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ABSTRACT 
Complex skeletal injuries and large bone fractures are still a significant clinical 
problem in US. Approximately 1.5 million Americans (veterans, their families, and 
civilians) every year suffer from bone loss due to traumatic skeletal injuries, infection, 
and resection of primary tumors that require extensive grafting to bridge the gap. The US 
bone graft market is over $2.2 billion a year. Due to insufficient mechanical stability, 
lack of vascularity, and inadequate resorption of the graft, patients with traumatic large 
skeletal injuries undergo multiple costly operations followed by extensive recovery steps 
to maintain proper bone alignment and length. Current strategies for repairing damaged 
or diseased bones include autologous or allograft bone transplantations. However, limited 
availability of autografts and risk of disease transmission associated with allografts have 
necessitated the search for the development of new bone graft options and strategies. 
The overall goal of this project is to develop a much-needed bone-mimetic 
engineered graft as a substitute for current strategies providing required bone grafts for 
reconstruction of large bone defects. This project will use the structure of natural cortical 
bone as a guide to produce an engineered bone graft with balanced strength, osteogenesis, 
vascularization, and resorption. The outcome of this project will be a biodegradable 
hybrid scaffold system (similar to natural cortical bone) including a mechanically strong 
scaffold allowing for mechanical stability of the load-bearing defect site and a soft and 
highly porous structure such as a hydrogel phase which will allow for efficient cell and 
vi 
 
growth factor delivery into the defect implantation site, cell niche establishment and 
promotion of mineralization. Successful completion of this project will transform bone 
graft technology for regeneration of complex bone defects from a frozen or freeze-dried 
allograft to a safe, infection-free, mechanically-stable, osteoinductive, and vasculogenic 
graft that is ultimately displaced by the patient’s own tissue. 
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CHAPTER 1: BACKGROUND INFORMATION 
1. General introduction  
Repair and restoration of damaged bone is a major clinical challenge as well as an 
economic burden. Current strategies for repairing damaged or diseased bones include 
autologous or allograft bone transplantations. However, limited availability of autografts 
and risk of disease transmission associated with allografts have necessitated the search 
for the development of new bone graft options and strategies 1. Tissue engineering has 
recently emerged as an alternative strategy for bone defect repair and regeneration. In this 
strategy, a biodegradable scaffold is often utilized along with osteogenic cells and/or 
bone inducing factors to mimic the natural structure of the tissue.   
 
 
Figure 1.1: Tissue engineering approach for reconstruction of large bone fractures
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Bone tissue is composed of an external layer, referred to as cortical or compact bone, 
and an internal layer, referred to as cancellous or spongy bone 2. Cortical bone makes up 
to ~80% of the total bone mass in adults. It is extremely dense, with low porosity (20%) 
and high mechanical strength (130-190 MPa). Cancellous (spongy) bone accounts for the 
other 20% of the total bone mass and is highly porous (50%–90%), to allow for better 
penetration of vasculature, with ~10% of the mechanical strength of cortical bone 3. 
Although cortical and cancellous layers are quite different in structure, they both contain 
a highly vascularized network. The presence of a vascular network is essential to supply 
nutrients and remove waste products. The main source of blood cells and vascular 
structures in bone is bone marrow 4. Bone marrow is a soft, gelatinous and highly 
vascularized connective tissue within bone cavities and the spaces between the trabeculae 
of spongy bone. Bone marrow is either red or yellow, depending upon the preponderance 
of hematopoietic (red) or fatty (yellow) tissue 5.  
A scaffold for bone regeneration should satisfy basic scaffold requirements such as 
biocompatibility, interconnected pore structure for tissue in-growth, and controlled 
degradation with physiologically-friendly degradation products 6, 7. In addition, an ideal 
bone tissue engineering graft should provide suitable weight-bearing mechanical 
properties and have both excellent proosteogenesis and proangiogenesis to rapidly realize 
the bone regeneration in vivo 8, 9.  
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Figure 1.2. Bone anatomy (Copyright ª 2004 Pearson Education, Inc., publishing as 
Benjamin Cummings). 
 
 In fact, the healing of bone defect is a complex, coordinated temporal process 
involving a myriad of molecular, cellular, biochemical and mechanical cues, among 
which angiogenesis, or neovascularization, is a critical factor for regenerative bone tissue, 
because the existence of a functional vascular network within the defect site can provide 
sufficient oxygen and nutrients to facilitate growth, differentiation, and tissue 
functionality, which is of particular importance for bone regeneration 10. Thereupon, a 
desirable scaffold which could provide high mechanical stability and promote 
angiogenesis as well as osteogenesis during the bone regeneration process is worthy of 
study.  
Although great strides have been made, it is difficult for any biomaterial to satisfy all 
of the listed requirements. To develop better scaffolds for bone regeneration, researchers 
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have attempted to integrate mechanically strong and porous scaffolds with soft and 
hydrated scaffolds such as hydrogels. These structures are referred to as hybrid scaffolds 
11, 12
. In this approach, the mechanically strong scaffold component would allow for 
mechanical stability of the load-bearing defect site; whereas, the hydrogel phase will 
allow for efficient cell delivery into the defect implantation site, cell niche establishment 
and promotion of mineralization. Hydrogels are polymeric, soft and flexible networks 
that have the ability to absorb and retain a large volume of water (80%–99%) without 
dissolving 13. Hydrogels can be made from natural biodegradable polymers such 
collagen, chitosan, and gelatin, or synthetic polymers such as polyethylene glycol (PEG) 
and polyvinyl alcohol 14, 15. Their remarkable properties, including similarities with the 
ECM, proper biological performance, hydrophilicity, high permeability to oxygen and 
nutrients, and inherent  cellular interaction capabilities, make them leading candidates for 
engineered tissue scaffolds 13. Also, growth factors for the promotion of accelerated bone 
and vascularization (i.e., BMP, VEGF) may also be covalently tethered to the hydrogel 
phase to allow for enhanced effects upon implantation. For instance, non-degradable 
hybrid scaffolds were fabricated by loading a self-assembling peptide into a porous 
titanium or polyetheretherketone cage to study bone regeneration in vitro and in vivo 11, 
12
. The observed bone regeneration was superior to hybrid grafts since the hydrogel phase 
offered a native environment for bone forming cells while the porous matrix 
mechanically supported bone regeneration 12. In addition, hybrid grafts offer the 
possibility of osteogenic cell and factor encapsulation. The newly developed “polymer-
hydrogel” hybrid system is robust: it not only satisfies mechanical needs but also has the 
ability to load the cells and factors required for osteogenesis and vasculogenesis 16. 
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Therefore, there is a clear need to develop biodegradable hybrid scaffold systems for 
effective bone tissue engineering.  
Shortly, the overall aim of the present study is to develop a biodegradable hybrid 
scaffold system (similar to natural cortical bone shown in figure 1.2) that is weight 
bearing and osteoinductive for effective bone regeneration (Figure 1.3). We will address 
the most critical challenges separately to design an optimized hybrid structure with the 
final goal of improving the bone healing process.   
 
 
Figure 1.3. Engineered cortical bone-mimetic scaffold 
 
The first major challenge in designing scaffolds for reconstruction of large bone 
defects is the graft’s mechanical stability and toughness. The engineered graft should be 
sufficiently rigid for closure of the skeletal gap to maintain homeostasis 17. Further, the 
engineered graft should be osteo-conductive/inductive and ultimately be replaced by the 
natural bone. The second major challenge in reconstruction of large bone defects is 
insufficient vascularization. Current tissue engineering strategies are extremely limited by 
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the lack of vascularization, leading to poor graft integration and failure of engineered 
substitutes in clinical trials 17. Since diffusion of nutrients and oxygen to the progenitor 
cells in the graft is limited to a few hundred micrometers, successful regeneration of large 
bone defects requires early induction of vascularization in the graft 18, 19. It is notable that 
the final effective bone regeneration and vessel formation in a critical sized defect are 
also attributed to the close association and interaction between angiogenesis and 
osteogenesis 20. One hand, most osteogenic factors such as Bone Morphogenetic Protein-
2 (BMP2) involved in osteogenesis stimulate angiogenesis, if not directly, then indirectly, 
through production of angiogenic molecules, such as Vascular Endothelial Growth Factor 
(VEGF) 16, 21. For example, it has been clarified that during endochondral ossification, 
there is close correlation between vascularization and bone formation as the maximum 
extent of bone formation follows maximum levels of VEGF expression 22. Therefore, the 
engineered graft should provide a compliant permissive environment such as a hydrogel 
phase which allows for efficient cell delivery into the defect implantation site, cell niche 
establishment and promotion of vascularization and osteogenesis 23. The third challenge 
is timed-release of growth factors in their respective microenvironments. Interactions 
between cells play an important role in directing their function and differentiation. In 
vivo cellular communication is mainly through a cascade of chemical cues, such as 
protein interactions and growth factor signaling. Growth factors are known to affect 
cellular proliferation, migration, and differentiation during bone repair 24. Owing to the 
critical role of growth factors in controlling basic cellular functions, and their ability to 
directly elicit and arrange tissue regeneration, a wide range of growth factors has been 
tested for distinct therapeutic applications, including bone regeneration and 
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neovascularization of ischaemic tissues. For instance, bone morphogenetic protein-2 
(BMP-2), transforming growth factor-β (TGF-β), fibroblast growth factor (FGF), platelet-
derived growth factor (PDGF), insulin-like growth factor (IGF), endothelin-1, and 
vascular endothelial growth factor (VEGF) are involved in bone formation 25. BMP, 
PDGF, FGF, and VEGF have been shown to enhance migration of osteoprogenitor cells, 
while TGF-β, IGFs, and BMPs modulate their proliferation and differentiation 26. 
Additionally, VEGF and FGF are involved in initiating vascular growth during bone 
healing 25. The cross-talk between osteoblasts and endothelial cells (ECs) is conducted 
through the release of VEGF by osteoblasts, which act on ECs to promote angiogenesis, 
and through the release of BMPs by ECs, which act on precursor bone cells to promote 
osteoblastic differentiation. In addition, FGF has been shown to stimulate proliferation 
and migration of ECs 27 and also induce osteoblasts differentiation28. Therefore, one 
efficient way to obtain osteoinductivity and enhance repair of the critical sized bone 
defects is application of growth factors such as of BMP2 and VEGF as it has been largely 
reported 29. However, concerns about these bioactive strategies still remain, such as the 
uncontrollable dose and composition of the delivered growth factors, and a high 
degradation rate resulting from a high in vivo instability of the angiogenic factors 30. 
Currently, for the clinical therapy, BMP-2 in a high dosage thereafter a high cost need to 
be used, which is possibly accompanied by the contingent risk and side effect, such as 
excessive bone resorption and promotion of tumor angiogenesis 31, 32. Furthermore, it has 
been shown that the extent of bone formation in vivo depends on the duration of exposure 
of osteoprogenitor cells and endothelial progenitor cells to BMP2 and VEGF, 
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respectively 33-35. Therefore, the controlled delivery system of growth factors becomes 
increasingly necessary and important.  
To address these challenges, the idea is to utilize novel nanomaterials to mimic the 
shell-core structure of cortical bone which is composed of interconnected network of 
microcanals, and a compliant, permissive core with timed and localized release of BMP2 
and VEGF to form an osteoblastic-vascular niche (Figure 1.3). In nano scale, bone has a 
nanocomposite structure made of collagen type I nanofibers (~ 30 wt%) and 
hydroxyapatite nanocrystals (~ 70 wt%) .  The superior mechanical stability and 
osteoinductivity of cortical bone in the natural tissue stem from the presence of high 
amount of hydroxylapatite nanocrystals on the surface of collagen nanofibers (Figure 
1.4a). Therefore, to address the first challenge, aligned polylactide (PLA) nanofibers with 
a tunable degradation time were mineralized with high quantity of calcium phosphate 
(CaP) nanocrystals by incubation in simulated body fluid (SBF) supplemented with bone-
derived organic acids (Ami 1, Figure 1.4b).  
 
Figure 1.4. a) Aim 1: Nanostrucuture of natural cortical bone. b) Engineering approach to 
mimic the nanostructure of cortical bone 
9 
 
Then, the CaP-nucleated nanofiber microsheets will be wrapped into microtubes and 
a set of microtubes will be assembled around a cylindrical mold and allowed to fuse by 
annealing above the glass transition temperature (Tg) of PLA nanofibers to form a rigid, 
tough, osteoconductive, cylindrical shell.  
As it was mentioned earlier, the main source of blood cells and vascular structures in 
bone is a soft, gelatinous and highly porous structure called bone marrow which is placed 
in the core of cortical bone and empty spaces in cancellous bone. Hence, to address the 
second challenge, a compliant hydrogel loaded with required cells and growth factors 
will be designed to form a osteoblastic-vascular niche in the structure of the engineered 
scaffold.  
 
Figure 1.5. Aim 2 and 3: Compliant hydrogel loaded with required cells and growth factors 
to mimic soft structure of bone marrow 
 
It should be also emphasized that osteogenesis and vascularization processes are 
coupled during the bone formation and regeneration as maximum extent of osteogenesis 
follows maximum level of vascularization and vice-versa. Therefore, in this work, a 
patterned hydrogel were designed to facilitate controlling both osteogenesis and 
vasculogenesis processes in the scaffold and consequently increase the extent of bone 
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formation. Moreover, to address the third challenge, a set of nanogels (NGs) were 
engineered to control the release rate of growth factors in patterned hydrogel. To do this, 
polyethylene glycol (PEG) chain-extended with short lactide (L) and glycolide (G) 
segments were used to form self-assembled NGs and facilitate a wide range of timed-
release for different types of growth factors such as BMP2 and VEGF.  
 
Accordingly, the following aims are considered to test the hypothesis toward the 
objectives. 
Aim 1. To engineer a cortical-bone-mimetic nanostructured shell by fabricating 
mineralized nanofibers and evaluate with respect to mechanical strength. 
osteoconductivity, and degradability.        
Ami 2. To synthesize resorbable, self-assembled, polyethylene glycol based nanogels and 
evaluate with respect to size, degardation rate and the release kinetics of BMP2- and 
VEGE-grafted nanogels. 
Ami 3. To evaluate the extent of vasculogenesis and osteogenesis of human 
mesenchymal stem cells (hMSCs) and human colony-forming endothelial cells (ECFCs) 
encapsulated in a patterned hydrogel with spatiotemporal release of BMP2 and VEGF.  
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CHAPTER 2: FABRICATION AND CHARACTERIZATION OF MINERALIZED 
NANOFIBERS USING SIMULATED BODY FLUID SUPPLEMENTED WITH 
BONE-DERIVED ORGANIC ACID 1 
1. Introduction 
Reconstruction of large incomplete bone segments remains a significant clinical 
problem 36, 37. Frozen allogeneic bone graft is used but the long-term failure rate of 
allografts in reconstruction of large segmental defects mainly due to infection and non-
union is 25%.37, 38 Demineralized bone matrix provides a supportive matrix for 
differentiation and maturation of osteoprogenitor cells but it fails to provide rigidity for 
segmental defects.39 Ceramics and polymers and their composites have been used to 
generate constructs matrices for regeneration of load-bearing bone defects.40  In 
particular, calcium phosphate (CaP) ceramics have attracted much attention as a bone 
substitute due to their osteoconductivity and osteointegrative properties41, 42 but they are 
brittle in tension and shear.43, 44  
 
 
 
1 Barati, D., et al., Effect of Organic Acids on Calcium Phosphate Nucleation and Osteogenic 
Differentiation of Human Mesenchymal Stem Cells on Peptide Functionalized Nanofibers. 
Langmuir, 2015. 31(18): p. 5130-5140.  
Reprinted here with permission of publisher. 
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Fiber-reinforced composites composed of calcium phosphates and degradable 
polymers can potentially have superior properties than their individual components but 
their properties are limited by the amount of CaP crystals that can be incorporated in the 
composite matrix.45-49 There is a need for composite biomaterials that can stabilize the 
regenerating volume, have tunable resorption, and support differentiation and maturation 
of osteoprogenitor cells.  
  Mineralization in bone is mediated by extracellular matrix (ECM) proteins rich in 
glutamic acid sequence.50, 51 In previous studies, we demonstrated that CaP contents as 
high as 200% (based on fiber weight) can be achieved on nanofiber microsheets by 
combining surface functionalization of the nanofibers with glutamic acid peptides and 
using a layer-by-layer CaP deposition approach to overcome the limited penetration of 
calcium and phosphate ions in the microsheets. The CaP content achieved in our previous 
study was higher than that of cancellous  bone (190%)52 but lower than the compact bone 
(>250%).10 Carboxylate-rich organic acids account for 5.5% of the organic matter in bone 
and citric acid plays a significant role in controlling crystallite size, growth and the extent 
of mineralization in the natural bone.53 Recently, it was reported that the spacing between 
the carboxylate groups in citric acid matches the spacing between calcium ions in the 
growing CaP nanocrystals.53-57 Citrate ions in the CaP nucleation solution inhibit the 
formation of large and stable crystals in solution58 and catalyze CaP nucleation on 
surfaces.59 
The objectives of this work was to investigate the effect of supplementing the 
nucleation medium with organic acids on the extent of CaP nucleation on the surface of 
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functionalized nanofiber microsheets and osteogenic differentiation of human 
mesenchymal stem cells (hMSCs) seeded on the surface of functionalized nanofiber 
microsheets through the following approach. The CaP nucleating peptide Glu-Glu-Gly-
Gly-Cys (EEGGC) was conjugated to relatively low molecular weight poly(DL-lactide) 
to produce a LMPLA-GLU conjugate. LMPLA-GLU conjugate was mixed with high 
molecular weight PLA and electrospun to generate aligned GLU-functionalized PLA 
nanofiber microsheets. The microsheets were incubated in concentrated simulated body 
fluid (SBF) supplemented with an organic acid to nucleate and grow CaP crystals on the 
surface of nanofibers. Citric acid (CA), hydroxycitric acid (HCA), tartaric acid (TART), 
malic acid (MA), salicylic acid (SalA) and ascorbic acid (AsA) were selected to tested 
organic acids with a range of carboxylic acid and hydroxyl groups.  
 
 
 
Figure 2.1. Nucleation of CaP crystals on the surface of nanofibers a. without addition of 
chealting agent, b. with addition of chelating agent such as citric acid 
14 
 
Carboxylic acid-rich organic acids like citric and malic acids account for 5.5% of the 
organic matter in natural bone.53 All tested organic acids are naturally present in fruit and 
vegetables. CA is the dominant organic acid in citrus fruits while MA is found in apple 
and pear.60 Tomato contains 9% CA, 4% MA, and 0.5% AsA based on dry mass.61 Rice 
and soybean contain SalA62 while grapes and grapefruit are a major source of TART and 
HCA.63, 64 The CaP nucleated microsheets were characterized with respect to particle 
size, crystallite size, percent crystallinity, calcium to phosphate ratio, CaP content, and 
compressive modulus. Next, CaP nucleated microsheets were seeded with hMSCs and 
cultivated in osteogenic medium. The cell-seeded microsheets were characterized by cell 
number, alkaline phosphatase (ALP) activity, and calcium content with incubation time. 
Results show that the addition of HCA, CA, and TART to the nucleation solution 
significantly increased the CaP content of the microsheets whereas only the addition of 
CA and AsA to the nucleation solution significantly increased osteogenic differentiation 
of hMSCs seeded on the microsheets.  
2.  Experimental 
2.1. Nanofiber Electrospinning 
The solution for electrospinning was prepared by dissolving 8 wt% PLA  and 1.5 
wt% LMPLA-GLU in HFIP (there was no LMPLA-GLU in “without GLU” samples” ) 
as we previously described.42 The electrospinning solution loaded in a 1 mL syringe was 
injected through a 21-gauge needle (PrecisionGlide, 0.7 mm I.D., Becton-Dickinson, 
Franklin, NJ) via a KDS100 syringe pump. The positive and ground electrodes of the 
high-voltage power source were connected to the needle and the custom-built rotating 
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wheel, respectively.42 The aligned nanofibers were electrospun using a 0.8 mL/h injection 
rate, 20 kV electric potential, 7.5 cm needle-to-needle distance, and wheel diameter and 
rotation speed of 20 cm and 1800 rpm, respectively, as we previously optimized.65-67 The 
collected aligned nanofiber microsheet from a 0.8 mL solution had a thickness of 6 µm. 
The average size of the aligned fibers was 200 ±60 nm.42 The electrospun PLA/LMPLA-
GLU nanofibers are hereafter denoted by NF. 
2.2. . Mineralization of NF in Modified Simulated Body Fluid 
A stock solution of 10-fold concentrated SBF (10xSBF) was prepared by dissolving 
NaCl, KCl, CaCl2•H2O, MgCl2•6H2O, NaH2PO4 in distilled deionized (DI) water as 
described.42 Next, one of the organic acids was added to the solution in concentrations 
ranging from zero to 15 mM. Molecular structure and pKa value of the organic acids are 
given in Table 1. Then, the pH of the solution was adjusted to 7.4 by addition of sodium 
bicarbonate (NaHCO3) to the mineralization solution. The solution was maintained at 
ambient conditions for 15-45 min to equilibrate and solution-nucleated CaP crystal was 
removed by filtration with a 220 nm pore-size filter. Next, the nanofiber microsheets 
were submerged in the organic acid-supplemented 10xSBF with agitation on an orbital 
shaker for 12 h. The containers were sealed with Parafilm to prevent diffusion of CO2 
from the atmosphere and maintain a constant solution pH. The nucleation solution was 
changed every 6 h to maintain a constant concentration of calcium and phosphate ions in 
solution with incubation time. The NF microsheets mineralized in 10xSBF solution 
supplemented with TART, HCA, CA, MA, AsA and SalA are hereafter denoted by 
TART, HCA, CA, MA, AsA and SalA, respectively.   
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2.3. Characterization of CaP-Nucleated Nanofiber Microsheets 
The extent of CaP nucleation and growth on NF microsheets was measured using a 
QuantiChrom calcium assay (Bioassay Systems, Hayward, CA) according the 
manufacturer’s instructions.42  
 
 
Table 2.1. Molecular structure and pKa of the organic acids. 
 
 
 
Briefly, the calcium content of 1 mg NF microsheet was dissolved in 0.4 mL of 1M 
HCl. Next, 5 µL aliquot of the suspension was added to 200 µL of the kit working 
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solution. After 3 min incubation at 37°C, absorbance was measured on a Synergy HT 
plate reader at a wavelength of 612 nm and correlated to the equivalent amount of Ca2+ 
using a calibration curve constructed from reference solutions with known Ca2+ 
concentrations. The total CaP content was determined from the measured Ca2+ content 
and calcium to phosphate (Ca/P) ratio obtained from energy-dispersive X-ray spectrum 
(EDS) of the sample. The measured CaP content was divided by the weight of NF sheet 
to determine CaP weight percent in each sample with incubation time in nucleation 
solution. The CaP-nucleated nanofiber microsheets were imaged with a VEGA3 SBU 
variable pressure scanning electron microscope (SEM; Tescan, Kotoutovice, Czech 
Republic) at an accelerating voltage of 8 KeV. Samples were coated with gold using a 
Denton Desk II sputter coater (Moorestown, NJ) at 20 mA current for 75 sec. The 
average fiber size of the microsheets and CaP particle size were determined from the 
analysis of SEM images using the ImageJ software (National Institutes of Health, 
Bethesda, MD) as described previously.42 An EDS system (Tescan) connected to the 
SEM was used to analyze the samples for elemental composition and Ca/P ratio of the 
samples as described.68 
Crystallinity and crystallite size of the nucleated CaP on microsheets were measured 
by wide-angle X-ray diffraction (XRD) using a Philips 405S5 diffractometer (Eindhoven, 
Netherlands) as we previously described.68 The diffraction spectrum was collected with a 
CuKα radiation source (λ=1.54059 Å) at 30 KeV over Bragg angles (2Ө) ranging from 
10 to 50 degrees with a step size of 3 degrees/min-1. Average crystallite size (L) of CaP 
particles nucleated on the microsheets was calculated from the XRD spectrum using 
Scherrer equation 69, 70 
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θβ
λ
=
cos
KL                                                                       (1)     
where K  is a shape factor with a value close to unity, λ  is the X-ray wavelength, β  
is full width at half maximum (FWHM) of the peak at the diffraction angle θ . The (002) 
reflection peak (2Ө=25.8) in the XRD spectrum was used to calculate crystallite size of 
the CaP particles as described. 71, 72 The fraction of crystalline phase in the CaP 
nanoparticles ( CX ) was calculated using the following equation developed for calcium 
phosphate crystals73  
300
300/1121
I
X C
ν
−≈
                                                                              (2)  
where 300I  is intensity of the (300) diffraction peak and 300/112ν  is intensity of the 
hollow region between (112) and (300) diffraction peaks in the XRD spectrum of the 
samples.   
For determination of compressive modulus, a 10 layered nanofibrous microsheets 
with the overall thickness of 60 µm was loaded on the Peltier plate of an AR2000 
rheometer (TA Instruments, New Castle, DE) and subjected to a uniaxial compressive 
force at a displacement rate of 7.5 mm/s.  The slope of the linear fit to the stress–strain 
curve for 5–10% strain was taken as the elastic modulus (E) of the mineralized matrix as 
we previously described.74 For determination of mass loss, the annealed samples were 
incubated in simulated body fluid (SBF) at 37ºC and under mild agitation.  At each time 
point, samples were removed from SBF, washed three times with DI water and dried 
under vacuum. The dry sample weight was measured and compared with the initial dry 
weight to determine the fractional mass remaining as described 75. 
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2.4. Cell Seeding on Mineralized Microsheets 
hMSCs were cultivated at 5000 cells/cm2 in a high glucose DMEM medium 
supplemented with 10% FBS, 100 units/mL penicillin and 100 µg/mL streptomycin 
(basal medium) with medium refreshment every three days. After reaching 70% 
confluency, the cells were detached with 0.1% trypsin- 0.03% EDTA and sub-cultivated 
at a ratio of 1:3 for <5 passages, according to supplier’s instructions. For cell seeding, 
edges of the microsheets on 12 mm circular glass coverslips were covered with a 
medical-grade silicone sealant (Dow Corning, MI) to prevent separation of the 
microsheet from coverslip in the cell culture medium. The microsheets were sterilized by 
ultraviolet (UV) radiation for 1 h followed by immersion in 70% ethanol for 30 min and 
washing three times with sterile PBS. We have previously shown that fiber alignment and 
size, or attachment of CaP nanoparticles nucleated on the fibers are not affected by the 
sterilization procedure.42 After incubation in basal medium for 1 h, each microsheet 
sample was seeded with 60 µL hMSC cell suspension (1.7x106 cells/mL in basal 
medium) at a surface density of 1x105 cells/cm2. After incubation for 24 h for cell 
attachment, the medium was replaced with osteogenic medium (basal medium plus 100 
nM dexamethasone, 50 µg/mL ascorbic acid, 10 mM ß-glycerophosphate). CA 
microsheets seeded with hMSCs and incubated in basal medium was used as the control 
group. The hMSC-seeded microsheets were incubated in a humidified 5% CO2 incubator 
for 21 days.  
2.5. Osteogenic Differentiation of Cell-Seeded Mineralized Microsheets 
At each time point (0, 7, 14 and 21 days), cell-seeded microsheet samples were 
washed with serum-free DMEM for 8 h to remove serum proteins followed by washing 
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with PBS. Next, samples were lysed with 10 mM Tris supplemented with 0.2% triton in 
PBS and the lysed samples were used for measurement of DNA content, ALP activity, 
and calcium content. Double-stranded DNA content, ALP activity and calcium content of 
the samples were measured with Quant-it PicoGreen, QuantiChrom ALP and 
QuantiChrom Calcium Assays, respectively, as we previously described. 42, 75 To 
determine the extent of mineralization of the samples by the seeded hMSCs at each time 
point, the measured calcium intensities at time zero was used a baseline to subtract the 
calcium contribution from the CaP-nucleated fibers prior to cell seeding. The measured 
ALP activities and calcium contents were normalized to cell number by dividing to DNA 
content at each time point. For imaging the extent of hMSC-induced mineral deposition, 
the microsheets were stained with Alizarin red using the following procedure. The cells 
on the microsheets were fixed with 10% paraformaldehyde. Next, the fixed samples were 
covered with a solution of Alizarin red, prepared according to the manufacturer’s 
instructions, and incubated in the dark at ambient conditions for 20 min. Then, a Nikon 
Optiphot epifluorescence microscope was used to image the samples for extent of nodule 
formation and the images were analyzed for average size of the nodules by the ImageJ 
software as we previously described 42.  
2.6. Statistical analysis. 
 Data are expressed as means ± standard deviation. All experiments were done in 
triplicate. Significant differences between groups were evaluated using a two-tailed 
Student's t-test. A value of p<0.05 was considered statistically significant. 
21 
 
3. Results  
3.1. CaP nucleation on the mineralized microsheets 
Figure 2.2a and 10b show the percent CaP nucleated on the microsheets with GLU 
(1a) or without GLU (1b) as a function of organic acid concentration in 10xSBF. CaP 
content of the GLU incorporated microsheets incubated for 12 h in 10xSBF without the 
addition of organic acids was 160±20%. That was significantly higher than the CaP 
content of the “without GLU” microsheets incubated for 12 h in 10xSBF (40%, see 
Figure 2.2b).  SalA and AsA did not significantly affect CaP content of “with GLU” 
microsheets at concentrations <4mM. CaP content of the “with GLU” microsheets 
increased to 170±10% and 175±5%, respectively, as SalA and AsA concentrations 
increased to 10 mM and CaP content remained unchanged with further increase in SalA 
or AsA concentration. CaP content of the “with GLU” microsheets peaked at 200%±20 
as MA concentration increased to 8 mM and then decreased to 185%±15 at MA 
concentration of 15 mM. CaP content of the “with GLU” microsheets incubated with CA, 
TART, and HCA increased with organic acid concentration, peaked at 6 mM 
concentration, and then decreased with increasing organic acid concentration. CaP 
content of the “with GLU” microsheets incubated with 6mM concentration of CA, 
TART, and HCA was 225±30%, 225±20% and 240±25%, respectively, but CaP content 
decreased to 200±20%, 205±15% and 215±20% at 15 mM organic acid concentration. 
The CaP content of “without GLU” microsheets increased from 40 wt% to a maximum of 
103, 114, 133, 155, 160 and 175 wt% when the nucleation medium was supplemented 
with SalA, AsA, MA, CA, TART and HCA, respectively. The peak CaP content of the 
“with GLU” microsheets incubated with 6 mM HCA was comparable with CaP content 
22 
 
of the natural compact bone.10 Figure 2.3 shows CaP content of the “with GLU” 
microsheets as a function of incubation time in 10xSBF supplemented with one of the 
organic acids at a concentration corresponding to the peak CaP content in Figure 2.2. In 
Figure 2.3, “None” represents the group without addition organic acids and Ctrl 
represents the group without addition of neither organic acid nor GLU. CaP content of 
the microsheets monotonically increased with incubation time in the first 16 h and 
reached a plateau at longer times. CaP content did not change significantly when 
incubation time was increased from 16 to 24 h for all organic acids and the plateau CaP 
content was highest for HCA supplemented 10xSBF at 244±10% and lowest for SalA at 
174±8%. Results in Figures 2.2-2.3 show that the addition of HCA to 10xSBF had the 
greatest effect on CaP content of the microsheets followed by TART, CA, and MA. 
Further, the optimum concentration and optimum incubation time was 6 mM and 12 h, 
respectively.  
 
 
Figure 2.2. Effect of organic acid concentration added to the concentrated SBF on CaP 
content of DL-PLA nanofiber microsheets (a) with and (b) without GLU for different organic 
acids after 16 h incubation.  
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Figure 2.3. Effect of incubation time in the concentrated SBF supplemented with different 
organic acids on CaP content of DL-PLA nanofiber microsheets at organic acid concentration 
corresponding to maximum CaP content in Figure 2.2.  
Figure 2.4 shows XRD spectra of the mineralized “with GLU” microsheets after 
incubation for 12 h in 10xSBF supplemented with optimum concentration of the organic 
acid (Figure 2.2a). The XRD spectra of pristine nanofiber microsheet without CaP 
nucleation (PLA) and pure hydroxyapatite (HA) are also included in Figure 2.4.  The 
broad diffraction peak in the spectrum of pristine PLA microsheet centered at 2Ө = 16° is 
characteristic of the amorphous poly(DL-lactide).76 Calcium phosphates that mineralize 
from solution at ambient conditions are HA, amorphous calcium phosphate (ACP), 
dicalcium phosphate dihydrate (DCPD), and octacalcium phosphate (OCP). 77, 78 The 
relatively sharp diffraction peaks in the spectra of HA and mineralized microsheets 
centered at 2Ө = 25.8°, 31.8°, 32°, 33°, and 46° corresponded to (002), (211), (112), 
(300) and  (222) planes of HA, respectively. 72, 76-78 The relatively broad diffraction peak 
overlapping the HA peaks at 2Ө = 31.8°, 32°, and 33°, which was absent in the spectrum 
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of HA, was due to the formation of ACP in the mineralized microsheets.70, 77 The 
characteristic diffraction peaks for crystalline OCP (2Ө = 16° and 24°) and DCPD (2Ө = 
29.2°, 34.4°, and 11.4°) were absent in the spectra of mineralized microsheets72, 77, 78. 
 
 
Figure 2.4. X-ray diffraction spectra of DL-PLA nanofiber microsheets with GLU incubated 
in the concentrated SBF supplemented with HCA, TART, CA, MA, AsA, and SalA organic acids 
for 16 h at the concentration corresponding to the maximum CaP content in Figure 2.3.  
 
 The EDS spectra of the mineralized “with GLU” microsheets incubated in 10xSBF 
for 12 h with optimum concentration (Figure 2.2) of HCA, TART, CA, MA, AsA, and 
SalA are shown in Figures 2.5a through f. The elemental Ca/P ratio calculated from the 
calcium and phosphorous peaks in Figure 2.5 and EDS data for “without GLU” 
microsheets (data not shown) are presented in Table 3 together with crystallinity and size 
of the crystallites (XRD images) and size of the CaP particles nucleated on nanofibers of 
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the microsheets (SEM images). Crystallinity of “with GLU” microsheets incubated in 
10xSBF without organic acids was 21±2%. TART and AsA incubated microsheets 
(TART and AsA) had the highest and lowest percent crystallinity, respectively, among all 
organic acids with 39±2% and 20±2%. SalA, HCA, CA, and MA incubated microsheets 
(SalA, HCA, CA, and MA) had percent crystallinity of 23±1%, 31±1%, 30±1%, and 
35%±3, respectively, which was in the range of crystallinity of cortical and cancellous 
bone (33-37%).79 The size of crystallites ranged between 31±2 and 62±4 nm with TART 
and Sal having the lowest and highest crystallite size, respectively. In comparison, the 
crystallite size for the “with GLU” microsheets mineralized in the absence of organic 
acids was 60±5 nm. Ca/P ratio of the microsheets ranged between 1.68±0.03 for TART 
and 1.91±0.05 for AsA with the microsheets mineralized in the absence of organic acids 
having a Ca/P ratio of 1.88±0.1. TART incubated “with GLU” microsheets  had Ca/P 
ratio of 1.68 which was closest to that of natural bone at 1.67 79 followed by HCA and 
CA with Ca/P ratio of 1.71 and 1.77, respectively. Crystals formed on “without GLU” 
microsheets had lower crystallinity, higher Ca/P ratio and larger crystallite size compared 
to the ones formed on “with GLU” microsheets.  
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Figure 2.5. EDS spectra of DL-PLA nanofiber microsheets incubated in the concentrated 
SBF supplemented with HCA, TART, CA, MA, AsA, and SalA organic acids for 16 h at the 
concentration corresponding to the maximum CaP content in Figure 2.2. 
 
Figure 2.6a-b shows the mass loss of the mineralized “with GLU” microsheets with 
incubation time in SBF at 37°C. The mass remaining of pristine PLGA and PLA NFs was 
0 % and 68%±5, respectively, whereas the mass remaining of mineralized NFs ranged 
between 85 %±2 and 93 %±1 after 35 days of incubation in SBF.  
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Table 2.2. Percent crystallinity, calcium to phosphate (Ca/P) ratio, crystallite size, and 
particle size of calcium phosphates particles nucleated on DL-PLA nanofiber microsheets (a) with 
and (b) without GLU. 
 
 
 
 
 
The mass losses are magnified in Figure 2.6b to show the effect of organic acid 
added to 10xSBF on mass loss of the mineralized microsheets. HCA with 12 %±2 mass 
loss had the slowest degradation while SalA with 19 %±3 mass loss had the fastest 
degradation among mineralized NFs after 42 days.  
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Figure 2.6. (a) Mass loss of DL-PLA nanofiber microsheets incubated in the concentrated 
SBF supplemented with HCA, TART, CA, MA, AsA, and SalA organic acids for 16 h at the 
concentration corresponding to the maximum CaP content in Figure 2.2. In (b) the y-axis is 
expanded (100-95% mass remaining) to show mass remaining for the mineralized microsheets. 
PLGA NF and PLA NF are PLGA and DL-PLA nanofiber microsheets with GLU and without 
incubation in SBF. There was not a significant pair-wise difference between the mass loss of CA 
and MA, CA and TART, and TART and MA groups by ANOVA test. There was a significant 
pair-wise difference between the mass remaining of other groups. Error bars correspond to 
means±1 SD for n=3. 
 
SEM images in Figure 2.7 and Figure 2.8 show the effect of organic acid added to 
10xSBF on size and distribution of the CaP nanoparticles nucleated on nanofibers of the 
“with GLU” and “without GLU” microsheets respectively. The average size of the 
nucleated CaP nanoparticles determined from the SEM images is presented in Table 3. 
The average particle size on “with GLU” microsheets ranged from 95±8 nm for TART to 
180±9 nm for SalA whereas the average particle size on “without GLU” microsheets 
ranged from 110±9 nm for TART to 270±33 nm for SalA. The size of the CaP crystals 
formed on both “with GLU” and “without GLU” microsheets in the organic acid 
incorporated solutions were significantly lower than the size of the ones formed in the 
absence of organic acids (None groups in Figure 2.7 and Figure 2.8). The number density 
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of CaP nanoparticles in AsA and SalA samples was lower than that of the other organic 
acid incorporated samples, consistent with the lower CaP content of AsA and SalA 
microsheets (see Table 4). The effect of organic acid in CaP nucleation medium on 
compressive modulus of the microsheets is presented in Table 4. Modulus of the “with 
GLU” and “without GLU” microsheets increased by 2.9 and 10.0 folds with CaP 
nucleation in the absence of organic acids in the nucleation solution (None group in Table 
3). The modulus of both “with GLU” and “without GLU” microsheets significantly 
increased with incorporation of organic acids within the nucleation solution. Furthermore, 
the modulus of “with GLU” microsheet was significantly higher than the one for 
“without GLU” microsheet in the presence or absence of organic acids.    HCA “with 
GLU” microsheets with CaP content of 240±10 wt% had the highest modulus of 260±40 
MPa compared to other mineralized microsheets which was 21.7-fold higher than the 
modulus of pristine DL-PLA microsheets 
 
Table 2.3. Maximum CaP content and compressive modulus of DL-PLA nanofiber 
microsheets with and without GLU incubated in the concentrated SBF supplemented with 
different organic acids. 
 
. 
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Figure 2.7. SEM images of DL-PLA nanofiber microsheets with GLU incubated in the 
concentrated SBF supplemented with HCA (a), TART (b), CA (c), MA (d), AsA (e), and (f) SalA 
for 16 h at the concentration corresponding to the maximum CaP content in Figure 2.2. None 
SEM image is DL-PLA nanofiber microsheets with GLU incubated in the concentrated SBF 
without the addition of organic acids for 16 h at the concentration corresponding to the maximum 
CaP in Figure 2.2. 
 
3.2. Osteogenic differentiation of hMSCs on nanofiber microsheets 
hMSCs were seeded on mineralized microsheets and cultured in complete osteogenic 
medium (basal medium plus dexamethasone, ascorbic acid (0.3 mM), ß-
glycerophosphate).  
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Figure 2.8. SEM images of DL-PLA nanofiber microsheets without GLU incubated in the 
concentrated SBF supplemented with HCA (a), TART (b), CA (c), MA (d), AsA (e), and (f) SalA 
for 16 h at the concentration corresponding to the maximum CaP content in Figure 2.2. None 
SEM image is DL-PLA nanofiber microsheets without GLU incubated in the concentrated SBF 
without the addition of organic acids for 16 h at the concentration corresponding to the maximum 
CaP in Figure 2.2. 
 
Experimental groups were hMSCs seeded on “with GLU” microsheets mineralized 
in the absence of organic acids (None) or presence of CA, AsA, SalA, HCA, MA and 
TART organic acids within the nucleation solution. hMSCs seeded on CA group and 
cultured in basal medium (CA-BM) was used as a control. DNA content of hMSCs 
cultured on the NF microsheets is shown in Figure 2.9. DNA content of the hMSCs in the 
control CA-BM group (black diamond) increased slightly with incubation time while the 
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DNA content of groups incubated in osteogenic medium decreased slightly with time. 
We have previously shown that at high initial cell seeding density used in our 
experiments, cell content of the microsheets decreases with incubation time as the cells 
undergo osteogenic differentiation.42 DNA content of hMSCs seeded on CA, AsA, SalA, 
HCA, MA and TART with a seeding density of 105 cells/ cm2 and incubated in 
osteogenic medium decreased slightly over 7 days of culture (Figure 2.9a) while the 
DNA content of hMSCs seeded on the same groups with two orders of magnitude lower 
seeding density (103 cells/cm2) increased significantly after 7 days of culture within the 
osteogenic medium.  
ALPase activity of hMSCs seeded on NF microsheets is shown in Figure 2.9b. 
ALPase activity of hMSCs seeded on CA-BM group incubated in basal medium did not 
increase significantly with time (black diamond). ALPase activity of hMSCs in CA, AsA 
and SalA groups peaked to the value of 5800±300, 5300±250 and 4800±150 IU/mgDNA, 
respectively at day 14, which was higher than that of None group with 4500±300 
IU/mgDNA at day 14. The peak value of ALPase activity for hMSCs seeded on HCA, 
MA and TART microsheets was 3800±200, 3200±100 and 3000±150 IU/mgDNA, 
respectively, after 14 days which was lower than that for None group. Calcium content of 
hMSCs seeded on mineralized NFs and cultured in osteogenic medium (basal medium for 
CA-BM) group is shown in Figure 2.9c. All calcium content values were subtracted from 
the values at day 1 to isloate the Ca deposited by cells from CaP deposited on fibers prior 
to cell seeding. Calcium content of the hMSCs seeded on CA-BM did not significantly 
change after 21 days of incubation in basal medium. The calcium content of all other 
groups increased slightly from day 4 to 7 and then increased monotonically over 21 days. 
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The calcium content of CA, AsA was 1200±100 and 1100±100 (mg/mg DNA) 
respectively after 21 days of incubation, higher than calcium content of None group 
(980±85 mg/ mg DNA). Calcium content of SalA, did not have a significant difference 
with that of None group at day 21. Calcium content of HCA, MA and TART groups was 
750±60, 610±50 and 550±55 mg/mgDNA, respectively, after 21 days of incubation 
which was lower than the calcium content of None group.  
 
 
Figure 2.9. DNA content (a) ALP activity (b) and calcium content (c) of hMSCs seeded on 
mineralized DL-PLA nanofiber microsheets with GLU as a function of incubation in osteogenic 
medium. CA-BM group (black diamond) is CA group incubated in basal medium, group 
incubated in osteogenic medium. Error bars correspond to means±1 SD for n=3. 
 
Image in Figure 2.10 show Alizarin Red Staining of hMSCs seeded on “with GLU” 
mineralized NF microsheets and cultured in osteogenic medium for 21 days. Controls 
included NF microsheets without CaP deposition and without hMSCs seeding (NF, 11i), 
NF microsheets with CaP deposition and without hMSCs seeding (NF+CaP, 11h) and NF 
microsheets with CaP deposition in the absence of organic acids within the nucleation 
solution and seeded with hMSCs (None, 11g). The presence of dark red areas in Figure 
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2.10a-g as opposed to Figure 2.9h and 2.10i showed the contributing effect of hMSCs to 
mineralization. A relatively high density of orange-red areas on the CA, AsA, SalA and 
None groups qualitatively confirmed a higher Calcium content (See Figure 2.10c) of the 
aforementioned groups compared with that of  MA, TART and HCA groups. Formation 
of bone nodules, three dimensional specifically mineralized and organized structures with 
proliferation, differentiation and mineralization stages of hMSCs simultaneously  80, was 
observed as large dark spots only on the CA group (see Figure 2.10b). The number 
density and total area of bone nodules on the CA group was 86 counts/cm2 and 1.8 ± 0.2 
mm
2/cm2.  Dark spots on the AsA and None groups (see Figure 2.10e and 2.10g) were 
smaller (<35 µm) to be considered as bone nodules based on the previous reports 80, 81 . 
4. Discussion 
In this work, we investigated the effect of organic acids with different number of 
hydroxyl and carboxylic acid groups (see Table 1) in the simulated body fluid on the 
extent of CaP nucleation on nanofiber microsheets . An attractive approach to retard CaP 
crystal nucleation in solution and enhance nucleation on the fiber surface is to increase 
the solubility of calcium and phosphate ions in the nucleation solution.78 Carboxylate-rich 
organic acids like citric acid which account for 5.5% of the organic matter in the natural 
bone,53 inhibits CaP crystal nucleation in solution.58, 59 Citric acid () with three 
carboxylate groups is ionized to citrate ion (	) (hereafter referred as Cit) in 
10xSBF nucleation medium.  
35 
 
 
 
Figure 2.10. Alizarin red staining of hMSCs seeded on mineralized DL-PLA with GLU and 
incubated in osteogenic medium for 21 days. NF+CaP and NF groups are mineralized and 
pristine nanofiber microsheets, respectively. 
 
Subsequently, the citrate ions are adsorbed on the surface of positively charged 
calcium ions to form a Ca-Cit complex. The negatively charged Ca-Cit complex is 
electrostatically repelled by the phosphate ions (PO43-) 53, 58, 82. The stability of Ca-Cit 
complex in solution depends on Cit concentration with the chelated Ca(Cit)- complex 
formed at low Cit concentrations72 and the stable [Ca(Cit)2]-4 complex formed at high Cit 
concentrations.59 Therefore, the presence of Cit ions at low concentration inhibits the 
formation of CaP crystals in the nucleation solution, effectively increasing the probability 
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of CaP nucleation on GLU sites on the surface of nanofibers. Consequently, CaP content 
of the NF microsheets increased with increasing CA concentration from zero to 6 mM in 
the presence of Ca(Cit)- complex. As the CA concentration was increased to values >6 
mM, the stable [Ca(Cit)2]-4 formed at high concentrations inhibited CaP nucleation  on 
the fiber surface.59 HCA, TART, MA, SalA, and AsA organic acids form complexes with 
Ca ions in the nucleation solution through their carboxylate groups similar to that of citric 
acid.83 Therefore, the biphasic trend of CaP content of the NF microsheets observed in 
Figure 2.2 can be attributed to a change in the stability of organic acid-calcium complex 
with organic acid concentration in the nucleation solution.  
The maximum CaP content of “with GLU” NF microsheets after 12 h incubation in 
10xSBF supplemented with HCA, TART, CA, MA, AsA, and SalA was 240±10%, 
225±8%, 225±10%, 177±15%, 203±12%, and 170±6=7%, respectively, compared to 
160±12% without organic  acid. The difference in peak CaP contents can be attributed to 
the different number of carboxylic acid and hydroxyl groups in the organic acids. Higher 
number of carboxylate groups in the organic acid increased chelation between calcium 
ions and organic acid molecules in the nucleation solution83 whereas higher number of 
hydroxyl groups in the organic acid enhanced hydrogen bonding interaction between the 
Calcium-organic acid complex and the carboxylic acid groups and electronegative groups 
present on GLU as well as fiber surface. 59 According to Figure 2.2a and 1.1b, the CaP 
content of both “with GLU” and “without GLU” NF microsheets increased significantly 
with addition of organic acids to the nucleation solution. However, the peak values for 
calcium content were higher in “with GLU” microsheets. Therefore, while Calcium-
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organic acid complex can bind to the fiber surface in the absence of GLU, the presence of 
GLU contributed to the CaP nucleation significantly.  
CaP content of the NF microsheets decreased as the organic acid in the nucleation 
medium was changed from HCA with three carboxylic acids to TART and MA with two 
carboxylic acids and SalA with one carboxylic acid group (see Tables 2 and 4). Further, 
HCA with two hydroxyl groups resulted in higher CaP of the microsheets when added to 
the nucleation medium compared to CA with a single hydroxyl group although both 
organic acids had three carboxylic acid groups. Similarly, CaP content of the microsheets 
incubated in SBF supplemented with TART (two hydroxyl groups) was higher than MA 
with one hydroxyl group while both organic acids had the same number of carboxylic 
acids. The higher CaP content of the microsheets incubated in SBF supplemented with 
AsA compared with MA was attributed to the higher number of hydroxyl groups in AsA 
(three for AsA versus one for MA). CaP content of the microsheets was 240% after 12 h 
incubation in HCA-supplemented 10xSBF which was higher than the CaP content of 
natural cancellous bone (190%)52 and cortical bone (230%).10 The incubation time to 
reach 95% of the plateau CaP content was 10 h which was significantly lower than the 
reported 4 days of incubation for CaP nucleation on the collagen nanofibers in 1.5xSBF 
supplemented with CA.59 
XRD results demonstrated that the CaP nucleated on the NF microsheets was a 
mixture of HA and ACP. Further, the deviation of Ca/P ratio from that of pure HA (1.67, 
see Table 3) increased with decreasing crystallinity of the nucleated CaP on the 
microsheets. Therefore, the deviation of Ca/P ratio from that of HA was related to the 
changes in the amorphous phase of the CaP particles with a Ca/P ratio in the 1.2-2.2 
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range). 72, 77, 78, 84 The crystallinity of CaP particles on NF microsheets was highest when 
the nucleation medium was supplemented with TART or MA having two carboxylic acid 
groups which can be attributed to an optimal spacing of Ca ions on the surface of the 
growing crystals. The relatively large CaP particle size and crystallite size in microsheets 
incubated in AsA and SalA supplemented SBF (Table 3) can be attributed to the lower 
inhibitory effect of those organic acids on crystal growth. Since AsA and SalA had only 
one carboxylic acid group with a net negative charge of one, the propensity for complex 
formation with Ca ions on the fiber surface for AsA and SalA was lower than other 
organic acids with two or more carboxylic acid groups (see Table 3). The number of 
crystallites per CaP particle on the microsheets was calculated from the particle size, 
crystallite size, and crystallinity data in Table 3. The number of crystallites per particle on 
the microsheets incubated in SBF supplemented with HCA, TART, CA, and MA was 11, 
11, 10 and 11, respectively, whereas that number was 4 and 5 for AsA and SalA. 
Therefore, the number of growing crystals on the surface of NF microsheets decreased 
and the size increased for those organic acids with lower inhibitory effect toward crystal 
growth (see Table 2.3 and Figure 2.7). Since the number of crystallites per particle was 
greater than unity for all organic acids, the nucleated particles had a polycrystalline 
structure interconnected by an amorphous phase.72  
For equal CaP content, TART incubated microsheets with higher crystallinity had 
higher compressive modulus than CA incubated microsheets (see Table 4). The slower 
degradation of mineralized microsheets indicated that the CaP nanoparticles had slower 
degradation than the DL-PLA nanofibers.43 The difference in degradation of the 
mineralized microsheets (Figure 2.6b) was related to differences in crystallinity and CaP 
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content. For example, microsheets incubated with AsA supplemented SBF with lowest 
crystallinity but higher CaP content than SalA and MA incubated microsheets had fastest 
mass loss among all microsheets. Conversely, microsheets incubated with HCA 
supplemented SBF with highest CaP content but lower crystallinity than TART and MA 
incubated microsheets had slowest mass loss among all microsheets.  
The difference between DNA content of hMSCs seeded on the surface of mineralized 
fibers 1 day after culture could be related to the differences between the surface 
properties of mineralized fibers.  It has been reported elsewhere that the surface adhesion 
of human gingival fibroblasts cells on an amorphous HA (~25% crystallinity) coating 
surface was higher than that of surfaces coated with higher crystalline HA (~ 63% and 
97% crystallinity) 85. Therefore, a higher DNA content of AsA, Ca and SalA groups 
compared with those of MA, TART and HCA groups could be due to a lower 
crystallinity of CaP particles hence higher adhesion of cells to the surface of former 
groups. Based on ALPase and calcium measurements, the presence of CA or AsA in the 
nucleation solution of microsheets had a positive effect on osteogenic differentiation of 
hMSCs while the presence of SalA did not have a significant effect and the presence of 
HCA, MA and TART within the nucleation solution was counterproductive in osteogenic 
differentiation of hMSCs. The contributing effect of CA to osteogenic differentiation of 
hMSCs was consistent with a reported contributing effect of calcium citrate in bone 
healing 86.  Further, it was shown elsewhere that an incorporation of CA into a cellulose 
based hydrogel improved osteogenic differentiation of hMSCs 87. In addition, It is well 
established that the presence of AsA stimulates the osteogenesis through integrin-
mediated intracellular signaling 88. Addition of CA to the nucleation solution also 
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stimulated the formation of nodules >100 µm in size (Figure 2.10). Schecroun et al. 
reported that dexamethasone in the osteogenic medium inhibited nodule formation by 
hMSCs in 2D culture.80 Our results indicate that the addition of CA to the nucleation 
solution hence the presence of citrate ion on the fiber surface stimulates nodule formation 
by hMSCs even in the presence of dexamethasone within the culture medium.  
5. Conclusion 
In this work, the effect of organic acids added to the simulated body fluid on CaP 
nucleation and osteogenic differentiation of human MSCs on nanofiber microsheets 
functionalized with a CaP nucleating glutamic acid peptide. Glutamic acid-functionalized 
aligned DL-PLA nanofiber microsheets were electrospun by blending high molecular 
weight DL-PLA with low molecular weight PLA conjugated with EEGGC peptide. The 
nanofiber microsheets were incubated in concentrated SBF supplemented with different 
organic acids for nucleation and growth of CaP nanoparticles on the surface of 
nanofibers. Organic acids included citric acid (CA), hydroxycitric acid (HCA), tartaric 
acid (TART), malic acid (MA), ascorbic acid (AsA), and salicylic acid (SalA). Addition 
of organic acids to SBF significantly increased CaP nucleation on the fiber microsheets 
and the extent of CaP nucleation depended on the number of carboxylic acid and 
hydroxyl groups in the organic acid. HCA-supplemented group had the highest CaP 
content at 240±10% followed by TART and CA with 225±8% and 225±10%, 
respectively. CaP nanoparticles nucleated on the fiber surface in TART-supplemented 
group had Ca/P ratio (1.68) and crystallinity (39%) closet to that of natural bone. 
Microsheets in HCA-supplemented group had the highest compressive modulus of 
260±40 MPa followed by TART and CA with 225±8 and 225±10 MPa, respectively. The 
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presence of CA or AsA in the nucleation solution of microsheets had a positive effect on 
osteogenic differentiation of hMSCs while the presence of SalA did not have a significant 
effect and the presence of HCA, MA and TART within the nucleation solution was 
counterproductive in osteogenic differentiation of hMSCs. CA group also stimulated the 
formation of bone nodules on the microsheets. 
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CHAPTER 3: ENGINEERING A CORTICAL-BONE-MIMETIC 
NANOSTRUCTURED SHELL WITH INTERCONNECTED MICROCANALS 
1. Introduction 
Biodegradable scaffolds, as key artificial devices widely used in tissue engineering, 
aim to provide a desirable micro-environment that allows neo-tissue to be generated 
properly for repairing and replacing damaged tissues or organs. To improve the 
performance of tissue scaffolds, various material parameters, e.g. stiffness, porosity and 
permeability, have proven particularly crucial to determine the biomechanical 
environments within scaffold micro-architectures. The scaffold material and porous 
architecture design (here architecture refers to features 10 to 1,000 micrometres in size) 
play a significant role in tissue regeneration by preserving tissue volume, providing 
temporary mechanical function, and delivering biofactors.  Intuitively, the best scaffold 
for an engineered tissue should be the ECM of the target tissue in its native state. One of 
the crucial characterizations of a tissue engineering scaffold is possessing sufficient 
mechanical properties to fill up the void space of the defect and simulating that of the 
native tissue. Therefore, scaffolds should provide mechanical and shape stability to the 
tissue defect. The intrinsic mechanical properties of the biomaterials used for scaffolding 
or their post-processing properties should match that of the host tissue. Recent studies on 
mechanobiology have highlighted the importance of mechanical properties of a scaffold
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on the seeded cells. Additionally, a tissue engineering scaffold should provide void 
volume for vascularization, new tissue formation and remodeling so as to facilitate host 
tissue integration upon implantation. The biomaterials should be processed to give a 
porous enough structure for efficient nutrient and metabolite transport without 
significantly compromising the mechanical stability of the scaffold. On the one hand, 
increasing scaffold stiffness could lead to a potential decrease in porosity and 
permeability, which prevents the neo-tissue from proper ingrowth to the bulk of 
scaffolds. On the other hand, increasing scaffold porosity might lead to a higher 
permeability but the effective stiffness would be sacrificed.  Moreover, the biomaterials 
should also be degradable upon implantation (with a temporary resistance to 
biodegradation upon implantation) at a rate matching that of the new matrix production 
by the developing tissue.  
Bone is a natural complex porous composite with unique properties of remodelling to 
adapt its microstructure to external mechanical stress. Bone is also one of the tissues with 
the highest demand for tissue reconstruction or replacement. Cranial, maxillofacial, oral 
fractures and large bone defects are currently being treated by using auto- and allografts. 
These techniques have limitations in the clinical usage such as immune response, donor-
site morbidity, and lack of availability89-91. Therefore, the interest on artificial tissue 
grafts were recently considered in order to overcome limitations of traditional allo- or 
autografts, such as risk of immune rejection and pathogen transfer, pain and infection, or 
limited availability 7, 92. The overall aim of this study is to develop a much-needed 
autograft-bone-mimetic engineered graft as a substitute for allograft bone in 
reconstruction of large bone defects.  Bioresorbable scaffolds, i.e. porous constructs, 
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seeded with the appropriate type of cells, should provide a template for tissue 
regeneration, while slowly resorbing, to finally leaving no foreign substances in the body, 
thus reducing the risk of inflammation. A three-dimensional (3D) internal geometry, 
similar to bone morphology, and the retention of mechanical properties after implantation 
are required for scaffolds in order to maintain a tissue space of prescribed size and shape 
for tissue formation.  
 The cortical bone is a hollow center dens shell composed of smaller units called 
osteons that have microtube like structures with a central vascular channel inside for 
ensuring suitable nutrient/waste transport to the bone tissue 93. Laminated multilayers of 
CaP deposited collagen fibers forms the osteon microtubes. The extracellular matrix 
(ECM) of bone is a composite that primarily comprises hydroxyapatite (HA) (biological 
ceramics) embedded within a collagen matrix (biological polymers) and water (Figure 3.1 
a). Carbonated HA Ca10(PO4)6(OH)2 accounts for approximately 70 % of the weight of 
bone. The inorganic component provides compressive stiffness to bone.  Roughly one-
third of the weight of bone is composed of the organic matter, which is primarily type I 
collagen and ground substance. Type I collagen fibres are elastic and flexible, and thus 
tolerate stretching, twisting, and bending. Therefore, biocompatible and biodegradable 
engineered scaffolds which can mimic both nano and microstructure of osteons in cortical 
bone tissue would be strong candidates for bone tissue engineering applications. 
Numerous methods have been developed and employed to fabricate 3D scaffolds for 
tissue engineering applications. Although the conventional fabrication techniques such as 
solvent casting, Freeze-drying and Gas foaming/supercritical fluid processinghave 
produced scaffolds used in tissue engineering of various types, most of them are 
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incapable of producing fully continuous interconnectivity and uniform pore morphology 
within a scaffold. Additionally, the pore size, pore geometry and spatial distribution 
cannot be precisely controlled in these conventional processes. One of the main 
limitations of most conventional fabrication methods is the need of an organic solvent to 
dissolve polymers and other chemicals, as well as the use of porogens to create pore 
structures. Most solvents and porogens are toxic, and their residues in the scaffold may 
cause severe inflammatory responses. Also, the physical configuration of the scaffolds, 
which mediate the cell-cell and cell-scaffold interactions, exerts strong influence on the 
success of osteogenesis processes in vitro 94, 95. The success of engineered scaffold 
mostly depends on how closely the cell-scaffold interaction mimics that natural tissue in 
vivo. Both in vitro and in vivo studies have demonstrated that organic/inorganic 
composite fibrous scaffolds which can mimic nanostructure of natural bone, support 
attachment, differentiation, and proliferation of osteoblasts or mesenchymal stem cells 
(MSCs) and facilitate bone healing 96. However, investigations regarding the effect of 
fibrous composite scaffolds such as osteon-mimetic tubular scaffolds with 3D 
morphology on osteogenic differentiation of MSCs are still limited. To this end, we 
hypothesized that three dimensional structure of microtubes with well-defined pores 
could potentially mimic the microstructure of osteons in cortical bone and induce 
osteogenesis of MSCs. In order to test this hypothesis, we investigated the osteogenic 
differentiation potential of MSCs when seeded into microtubes engineered from CaP 
deposited aligned nanofiber microsheets that have an array of macropores to enhance 
diffusion of nutrients. The microtube structure fabricated by wrapping CaP deposited 
nanofiber layers around the stainless steel needles upon annealing wrapped nanofiber 
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microsheets above glass transation temperature (Tg).  The effect of tubular formation of 
CaP deposited microsheets on osteogenic differentiation of rat MSCs was investigated by 
cytochemical, and mRNA expression. Our results indicate that the 3D microtubes provide 
a promising microenvironment that enhances osteogenesis when compared to microsheet 
scaffolds.  
2. Experimental 
2.1. Fabrication of cortical-bone-mimetic scaffolds 
CaP-nucleated microsheets (discussed in Chapter 2) were wrapped tightly around a 
25 G needle between 10-30 times for form a microtube (Figure 3.1 b). Next, a set of the 
microtubes was packed around a stainless steel rod and the assembly was heated to a 
temperature above the Tg PLA (85°C) nanofibers to form a rigid, tough, osleoconduetive, 
cylindrical shell by fuse the microtubes. After cooling, the rod and microneedles (in the 
mierotubes) were removed to obtain a nanostructred cylindrical shell with Haversian-like 
microcanals (Figure 3.1 b). Then, an array of circular microholes was drilled by a 
scanning deep-ultraviolet laser micro-drilling system (Precision MicroFab) on the outside 
surface of the shell (500-1000 µm apart) traversing the shell thickness to generate 
Volkmann like microcanals. Microdrilling resulted in the formation of a shell with an 
interconnected network of microcanals to stimulate cell migration, vascularization, and 
bone formation within the shell wall after implantation.  
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Figure 3.1. (a) Natural structure of bone tissue from micron to nano scale. (b) Steps for 
fabricating biodegradable, rigid, osteoinductive and osteoconductive shell. 
 
2.2. Characterization of cortical-bone-mimetic scaffolds 
The porosity and density of the CaP nucleated NF microsheets before and after heat 
treatment were calculated using Eq. (1) and Eq. (2). The thickness and size of the 
microsheets were measured using a micrometer caliper (VWR, Atlanta, GA).  
Apparent	density	(mg/mm) 	=  !""#	$  	(%)
#!&'"  × )*$"	$"$	(+)
	           (1) 
Porosity	(%) = 1 − /"' #0	*	 !""#	(%/
+)
/"' #0	*	123	(%/+)
	                              (2) 
For determination of compressive modulus, the scaffolds were prepared with the 
overall thickness of 1 mm and diameter of 1 cm, was loaded on the Peltier plate of an 
AR2000 rheometer (TA Instruments, New Castle, DE) and subjected to a uniaxial 
compressive force at a displacement rate of 7.5 mm/s.  The slope of the linear fit to the 
stress–strain curve for 5–10% strain was taken as the elastic modulus (E) of the 
mineralized matrix as we previously described 74. For determination of mass loss, the 
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scaffolds were incubated in simulated body fluid (SBF) at 37ºC and under mild agitation.  
At each time point, samples were removed from SBF, washed three times with DI water 
and dried under vacuum. The dry sample weight was measured and compared with the 
initial dry weight to determine the fractional mass remaining as described 75. 
3. Results and Discussion  
Mineralization in osteons occurs under the function of glutamic-acid rich residues 
of bone sialoprotein and osteonectinon on hydroxyapatite nucleation 97, 98.  Therefore, 
peptides including polyglutamic acid sequences have been widely investigated to 
determine the interaction with nHA crystals. For example, Itoh et al. coated HA with the 
synthetic peptide (E7PRGDT), and seeded osteoblastic cells onto the surface. They 
demonstrated that the amount of E7PRGDT peptide containing polyglutamic acid 
sequence bound to HA was higher than passively adsorbed RGD at all coating 
concentrations due to high affinity of polyglutamic acid peptide to nHA crystals 99. In 
addition, Sarvestani et al. treated the surface of nHA particles with glutamic acid peptide 
(Ac-Glu6). It was indicated that the average density of elastically active chains in the 
PLEOF network increased significantly when nHA in the network were treated with the 
osteonectin-derived Ac-Glu6 100. Similar to others, in our previous study, conjugation of 
glutamic acid template peptide on NF significantly increased the CaP nucleation 
(Karaman et al. in press). Thus, in this study we used the glutamic acid conjugated NF to 
nucleate the CaP crystals. 50 wt% CaP to fiber ratio (GLU-NF/CaP50) was used to 
fabricate the osteon-mimetic microtubes. The micro-tubuler structure of the biofabricated 
scaffolds ideally mimics the osteons structures of bone tissue 101. 
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The effects of the heat treatment on nanofiber microsheets based on CaP to NF 
weight ratio porosity and density are shown in Figure 3.2 a and b, respectively. The 
results indicated that the porosity of the CaP nucleated microsheets after heating 
decreased significantly for all the test groups. In addition, the appeareant density of 
different CaP containing GLU-NF microsheets was increased significantly for each test 
group after heat treatment.  
 
Figure 3.2. The effect of heat treatment on porosity(a) and density(b) of microsheets 
 
The compressive modulus and strength of the shell was a strong function of the CaP 
content of the microsheels (Figures 3.3 a and b). The compressive modulus and strength 
of the shell with 240% CaP content were 2.5 GPa and 150 MPa (Figure 3.3 a and b), 
respectively, which was in the range of natural compact bone 102, 103. The degradation of 
the engineered shell was inversely related to CaP content (Figure 3.3 c). The shell with 
240% CaP content had <5% mass loss after 120 days of incubation in SBF, thus the shell 
can potentially provide rigidity during the callus formation stage of bone formation 104. 
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Figure 3.3. Compressive modulus (a) and strength (b) of the shell as a function of CaP 
content, (c) Mass loss of the shell with incubation time in SBF for CaP contents of 0, 120, 180 
and 240%. (d) Magnification of mass remaining results for 120, 180 and 240%. 
Also, the compressive modulus of microsheets before and after heat treatment is 
compared in Figure 3.3 a.  The heat treatment significantly increased the compressive 
modulus of the CaP nucleated NF microsheets.  For example, the compressive modulus 
of 120 wt% CaP microsheets increased from 0.12±0.02  GPa to 1.4±0.2 GPa. And that of 
240 wt% increased from 0.26±0.04  GPa to 2.4±0.3 GPa after heat treatment. These 
results indicated that the stiffness of  microsheets was increased by heat-shrinking the 
microsheets. Similar with our results, it has been reported that with the increasing of  
apatite amount in nanofibrous microsheets, the tensile modulus of the microsheets 
increases significantly 105. In addition, incorporation of nHA crystals in polycaprolactone 
fibers increases the tensile modulus of fabricated electrospun NF 106. Overall, nCaP 
deposited NFs have the potential to provide higher structural support to progenitor cells 
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compared to NF with no CaP content. It has been observed that increasing mineral 
content on NF significantly enhanced MSCs adhesion and differentiation107.  
The limitation of nanofibers fabrication with electrospinning is that it produces a 
relatively two dimensional fibrous scaffolds. In addition, the pore sizes are relatively 
smaller which does not allow cells to penetrate into the scaffold 108. Therefore, a rigid, 
resorbable, and osteoconductive shell with similar microstructure to cortical bone 
including interconnected network of microcanals to provide the mechanical stability 
needed for large bone fracture was designed in this study. Figure 3.4 shows the SEM 
images of different inner diameter microtubes made by 240 wt% CaP coated NF sheets.    
 
Figure 3.4. SEM images of different inner diameter microtubes 250 µm (a), 450 µm (b), and 
800 µm (c). 
 
Figure 3.5 shows a hollow center annealed scaffold containg 180 nucleated 
microtubes with 240 wt% CaP content. It can be observed in figures 3.5 a and b that this 
biofabrication technique results in formation of dens shell-like structure including several 
microchannels which mimics that of natural cortical bone (see natural cortical bone 
structure in figures 1.2 and 3.1). Additionally,   the microholes on the surface of scaffold 
can eb clearly seen in figure 3.5 c. The presence of these microholes can be resulted in 
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the formation of a shell with an interconnected network of microcanals to stimulate cell 
migration, vascularization, and bone formation within the shell wall alter implantation.  
 
Figure 3.5. A cortical bone-mimetic scaffold made by 180 microtubes. (a) Top view of the 
cross section of scaffold. (b) Side view of scaffold including the microholes. (c) Magnification of 
microholes in the scaffold. 
 
It has been reported that it takes 12 weeks for newly formed callus to become load-
bearing  as patients 104 undergoing alveolar bone reconstruction wait minimum of 12 
weeks for bone to form  on the regenerating membrane prior to tooth implantation 109. 
The engineered shell should resorb and transfer load to the newly formed bone to reduce 
stress-shielding after 24 weeks 110. The natural dense bone has <15% porosity 111), CaP to 
collagen fiber ratio of 200- 300% 52,   compressive modulus and strength of 5 GPa and 
90- 170 MPa, respectively 102, 103. Therefore, success is defined by <5% resorption of the 
engineered shell after 12 weeks, >75% resorption after 24 weeks, with initial and 12-
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weeks compressive strength of 150 MPa and 100 MPa, respectively. The product is an 
engineered, rigid, and resorbable shell with interconnected canals to allow vascularization 
and bone formation from within the shell wall. 
4. Conclusion 
In this study, our objective was to investigate the fabrication a 3D formation of 
microtubes acffold. The novel aspect of this work is the synthesis of a cortical-bone-mimetic 
shell with Haversian-/Volkmann-like canals for nutrient and oxygen supply to the 
migrating cells inside the shell. In this aim, aligned, functionalized. nanotmermicrosheets 
were nucleated with CaP naocrystals. Then the sheets were wrapped into microtubes, a 
set of mierotubes were fused to from a shell. Microhdles were drilled on the shell surface 
to form an interconnected network of canals for nutrient and oxygen supply. The shells 
will be evaluated with respect tq strength, resorption, and osteogenesis. The target 
compressive strength is 150 MPa, mass loss of <5% after 12 weeks and >75% after 24 
weeks. Present findings demonstrate that the 3D structure of microrubular scaffolds 
provide a promising microenvironment that enhances osteogenesis compared to 2D 
microsheet scaffolds.  
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CHAPTER 4: FABRICATION OF RESORBABLE, SELF-ASSEMBLED, 
POLYETHYLENE GLYCOL BASED NANOGELS FOR CONTROLLED 
RELEASE OF GROWTH FACTORS 1 
1. Introduction 
Bone morphogenetic proteins (BMPs) are the most abundant osteoinductive proteins 
which regulate the differentiation and function of cells involved in osteogenesis 112. 
Specifically, it has been proved that BMP-2 is present in different steps of bone healing, 
from the initial stages of bone regeneration as well as during later phases including 
osteogenesis and chondrogenesis 113, 114. Vascular endothelial growth factor (VEGF) as a 
widely used angiogenic growth factor in regenerative medicine plays a key regulatory 
role in up-regulation of angiogenesis by signaling vascular endothelial cells to undergo 
proliferation, migration, and differentiation into new blood vessels 115. VEGF's normal 
function is to create new blood vessels during embryonic development, new blood 
vessels after injury, muscle following exercise, and new vessels (collateral circulation) to 
bypass blocked vessels.  
 
 
1 Barati, D., et al., Spatiotemporal release of BMP-2 and VEGF enhances osteogenic and 
vasculogenic differentiation of human mesenchymal stem cells and endothelial colony-forming 
cells co-encapsulated in a patterned hydrogel. Controlled Release, 2016. 223: p. 126-136. 
Reprinted here with permission of publisher. 
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Therefore, an alternative approach like developing biocompatible carriers is 
necessary to control both the location and rate of growth factors delivery at the defect 
site. PLGA micro- and nanoparticles due to their wide range of degradation times are 
used for immobilization and timed-release of BMP2 and VEGF 118-121. However, protein 
denaturation by surface adsorption and acidic degradation products of PLGA can 
significantly reduce protein bioactivity 122, 123. Due to the hydrophilicity and chain 
flexibility of polyethylene glycol (PEG), PEGylation is used to increase stability of 
PLGA nanoparticles in aqueous suspensions, enhance stability of the grafted protein, and 
reduce particle phagocytosis 118, 120, 124-126. In this work, PEG macromers chain-extended 
with short lactide (L) and glycolide (G) segments were used to form nanogels (NGs) for 
grafting and timed-release of BMP2 and VEGF proteins. In the chain-extended 
macromer, the PEG block imparted stability to NGs in aqueous solution, L segment led to 
self-assembly and NG formation, and G segment controlled NG degradation and protein 
release. We have previously shown that PEG macromers chain-extended with short L/G 
segments form micellar structures in aqueous solution 127. Here, the effect of PEG 
molecular weight (MW) and L/G segment length on degradation and protein release 
kinetics of the NGs have been investigated.  
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Figure 4.1. Synthesis of PEG macromers chain-extended with short lactide (L) and glycolide 
(G) segments to form nanogels (NGs) for grafting and timed-release of BMP2 and VEGF proteins 
 
2. Experimental 
2.1. Synthesis and functionalization of PEG-LG block copolymer 
The PEG-LG block copolymers were synthesized by melt ring-opening 
polymerization with successive addition of L and G monomers to the reaction using PEG 
as the initiator and TOC as the catalyst. PEG and lactide were added to a reaction flask 
equipped with a stirrer and immersed in an oil bath in a molar ratio based on the desired 
L segment length (Table 4). Next, the flask was heated to 120°C under nitrogen flow and 
maintained at that temperature for 1 h to remove residual moisture. Then, TOC catalyst 
was added to the mixture at 120°C and the reaction was allowed to proceed for 6 h at 
140°C. The lactide chain-extended PEG
 
macromer was used as an initiator for chain 
extension with G monomer with a predetermined L to G ratio (Table 1). The reaction was 
allowed to proceed for 6 h at 140°C and the product was precipitated in ice-cold hexane 
to remove the unreacted monomers. The synthesized copolymer was functionalized with 
succinimide groups by reacting hydroxyl end-groups of the copolymer with DSC as we 
described previously 128. The product was purified by dialysis against DI water and 
lyophilized. The chemical structure of the synthesized copolymer was characterized by a 
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Varian Mercury-300 1H-NMR (Varian, Palo Alto, CA) as we previously described 129. 
The synthesized macromers are hereafter referred to as PaLGb-Lc (Tables 1 and 2) where 
the lowercase letter “a” is the PEG MW in kDa, “b” is LG to PEG molar ratio, and “c” is 
the mole fraction of lactide in LG segments. The shorter abbreviations P4-I,II,III, P8-
I,II,III, and P12-I,II,III stand for those macromers based on 4, 8, and 12 kDa PEG MW, 
respectively.  
2.2. Nanogel formation and protein grafting 
PaLGb-Lc macromer was dissolved in DMSO and self-assembled to form NGs by 
dialysis (3.5 kDa MW cutoff) against PBS for 8 h as we previously described 118. For 
BMP2 or VEGF grafting, 10 mg NGs was suspended in 0.5 mL PBS by sonication for 1 
min. Next, 0.5 mL of the protein in PBS (20 mg/mL for BSA, 800 ng/mL for BMP2 and 
VEGF) was added to the NG suspension. The amine group of the protein was allowed to 
react with succinimide end-groups of PaLGb-Lc in NGs under ambient conditions for 12 
h as we previously described (Figure 4.1) 119. The protein grafted NGs were freeze-dried 
to obtain a free flowing powder. To determine grafting efficiency, the protein grafted 
NGs were resuspended in PBS and centrifuged at 18,000 rcf for 10 min and the 
supernatant was analyzed for total protein content with the ninhydrin reagent as we 
described previously 130. Grafting efficiency was determined by dividing the amount of 
attached protein (total - free protein) by the initial amount in the grafting reaction. 
Size distribution of the NGs was measured by dynamic light scattering with a 
Submicron Particle Sizer (Model 370, NICOMP, Santa Barbara, CA) as we described 
previously 119. Polydispersity (PD) of the NGs was determined using the equation PD = 
∆d/ <d> where ∆d and <d> are the standard deviation and mean size of the NGs, 
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respectively 131, 132. Zeta potential of the NGs was measured with a ZetaPlus analyzer 
(Brookhaven Instruments, Holtsville, NY) with a particle concentration of 2.5 mg/mL at 
25°C in PBS 133. NGs degradation kinetic was measured by incubation in PBS at 37°C as 
we described previously 118. The fractional mass remaining was determined by dividing 
the dried mass at time t by the initial mass. For measurement of release kinetic, 1 mg 
protein grafted NGs were incubated in 1 mL PBS at 37°C as we previously described 118. 
At each time point, the suspension was centrifuged at 18350 rcf for 10 min, the 
supernatant was removed, the NGs were resuspended in 1 mL fresh PBS and incubated 
until the next time point. The amount of BSA in the supernatant was measured with the 
ninhydrin reagent as described 130. In the case of BMP2 and VEGF-grafted NGs, the 
protein concentration in the supernatant was measured by ELISA as we described 
previously 118.  
3. Results 
3.1. Macromer characterization 
The average number of L/G units per PaLGb-Lc was calculated from 1H-NMR 
spectra of the macromer. Two chemical shifts with peak positions at 1.6 and 5.2 ppm, 
two at 3.6 and 4.2 ppm and one at 4.8 ppm were attributed to the methyl and methine 
hydrogens of lactide, the methylene hydrogens of PEG and the methylene hydrogens of 
glycolide, respectively 128, 134. The chemical shift with peak position at 2.77 ppm was 
related to the methylene hydrogens of succinimide end-groups. The average segment 
length of L and G units per macromer and the number-average MW (
nM ) of the 
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macromers are shown in Table 4. The number of L and G units per macromer ranged 2.3-
8.9 and 0.9-5.7, respectively.  
3.2. Characterization of nanogels 
Size distribution of P4, P8, and P12 NGs and their corresponding SEM images are 
shown in Figures 4.3a to c, respectively. In general, mean size of the NGs was <200 nm. 
Mean size, PD, and zeta potential of the NGs are given in Table 5. Mean size ranged 
from 120±6 to 140±13 nm for P4 NGs, 150±11 to 160±17 nm for P8 NGs, and 170±12 to 
190±15 nm for P12 NGs, respectively.  
 
Table 4.1. Number average molecular weight (M_n ) ,̅ LG to PEG feed ratio, average 
number of L and G segments per macromer for PaLGb-Lc macromers. 
 
 
 
The NGs were relatively monodisperse with PD<0.2 and the mean NG size increased 
with decreasing lactide fraction. All NGs were negatively charged with zeta potential 
between -23 and -15 mV. The absolute value of the zeta potential increased with 
increasing PEG molecular weight while the lactide fraction did not significantly affect 
zeta potential.  
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Degradation of the NGs with incubation time was biphasic with an initial fast rate 
followed by a slow rate (Figure 4.2 a-c). Degradation rate increased with decreasing L:G 
ratio for all NGs. Mass loss of P4 and P8 NGs after 24 days incubation increased from 
50±5 to 65±3% and 60±8 to 85±2%, respectively, as the L:G ratio decreased from 75:25 
to 50:50. P12-I, P12-II and P12-III NGs degraded after 12, 16, and 18 days, respectively.  
 
Table 4.2. Mean size, polydispersity (PD) and zeta potential of NGs formed by PaLGb-Lc 
macromers. Error bars correspond to means ± 1 SD for n=3. 
 
 
 
P4-I NGs had the slowest degradation with 50±5% mass loss after 30 days and P12-
III NGs had the fastest degradation with >95% mass loss after 12 days. The release 
kinetic of BSA from the NGs in PBS was biphasic with an initial fast rate followed by a 
slow rate (Figure 4.3 d-f), consistent with NGs degradation. The release of BSA 
increased with decreasing L:G ratio for all NGs. The average BSA release rate of P4, P8, 
and P12 NGs increased from 2 to 4.2%/day, 4 to 6.3%/day, and 5.7 to 9.7%/day, 
respectively, as L:G ratio decreased from 75:25 to 50:50. P4-I had the slowest BSA 
release with 45±8% in 24 days and P12-III had the fastest with >95% released in 12 days.  
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Figure 4.2. Effect of PEG MW, LG segment length, and L/G ratio in PaLGb-Lc macromer 
on NG mass loss in PBS with incubation time.  The abbreviations P4, P8, and P12 represent NGs 
made from macromers with PEG MW=4, 8, and 12 kDa and average LG segment length of 8. 
The 
 
The extent of bone formation in vivo depends on the duration of BMP2 exposure to 
MSCs in the first four weeks 135, 136 whereas vascularization depends on VEGF exposure 
to endothelial progenitor cells within the first week 137. Figure 4.3 g represents the release 
rate of BMP2 and VEGF encapsulated inside SPELA and GelMA hydrogels, 
respectively, compared to BMP2 and VEGF grafted to NGs(21) and NG(10), 
respectively. It can be observed that the encapsulated BMP2 and VEGF were completely 
released from hydrogels in less than 40 hours while the ones attached to NG(21) and 
NG(10) were released steadily after 3 weeks and 7 days, respectively. Therefore, NGs 
with steady release for 3 weeks and 71±3 wt% bioactivity (P8-1 NGs) were used for 
BMP2 grafting; NGs with steady release for 7 days with 80±5 wt% bioactivity (P12-II 
NGs) were used for VEGF (Figure 4.3 g).  
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Figure 4.3. Effect of PEG MW, LG segment length, and L/G ratio in PaLGb-Lc macromer 
on NG size distribution (a-c), and cumulative BSA release (d-f) in PBS with incubation time. 
Release kinetic of BMP2 encapsulated in SEPLA and VEGF encapsulated in GelMA hydrogel 
compared to release kinetic of BMP2 grafted to NGs and VEGF grafted to NGs. The 
abbreviations P4, P8, and P12 represent NGs made from macromers with PEG MW=4, 8, and 12 
kDa and average LG segment length of 8. The abbreviations P4-I, P4-II, and P4-III represent NGs 
made from 4 kDa MW PEG macromers with 75%, 60%, and 50% lactide in the LG segments, 
respectively. The numbers in abbreviations NG(21) and NG(10) represent the release time of 
grafted proteins on each type of NG. Morphology of the dried NGs is shown in the inset SEM 
images in (a-c). Error bars correspond to means ± 1 SD for n=3. 
 
4. Discussion 
Size distribution of nanoparticles self-assembled from PEG-LG macromers depends 
on the rate of particle assembly which in turn is related to the length of hydrophobic LG 
segments 138. We previously generated nanoparticles (NPs) by self-assembly of ultra-low 
molecular weight ULMW-PLGA (1-2 kDa MW) with amphiphilic copolymers of PEG 
(3.4 kDa) and ULMW-PLA (PLEOF). The resulting NPs had mean sizes in the 200-300 
nm range and relatively wide size distributions from 100 to 600 nm 118. In this work, we 
used a different approach to generate PEG-LG macromers by extension of PEG chain-
ends with a short L segment followed with a short G segment. The average length of the 
L segments was 5-10 (Table 4, note two ends per chain) while it was 15-30 in the 
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previous approach with ULMW-PLAF/PLEOF 118. The relatively shorter hydrophobic 
segments in PaLGb-Lc led to the formation of hydrophilic NGs with mean sizes as low as 
120 nm and size distributions as narrow as 25-150 nm. The more hydrophobic L segment 
in PaLGb-Lc controlled NGs assembly whereas the less hydrophobic G segment 
controlled NGs degradation. 
 As the PEG MW was increased from 4 to 8 and 12 kDa in P4-I, P8-I and P12-I, 
the L segment length had to be increased from 2.3 to 3.8 and 5.4, respectively, to induce 
self-assembly for the macromer with 50/50 L/G ratio (Table 4). As the L segment length 
in P4-I, P8-I and P12-I increased, mean NG size increased from 118±6 nm to 141±11 and 
165±12 nm (Table 3), respectively. Length of the PEG block regulated the extent of 
association between the macromers by balancing van der Waals and dipolar interactions 
to prevent aggregation of hydrophobic LG segments 139. The measured NG sizes in Table 
5 are consistent with the previously reported increase in the average diameter of PLA-
PEG nanoparticles from 30 to 60 nm with increasing PLA block MW from 3 to 30 kDa 
140
. The measured zeta potentials of the NGs (-15 to -22 mv) was significantly less than 
the reported values for PLA or PLGA nanoparticles (~ -50 mv) 141 which was attributed 
to the negatively-charged carboxyl end-groups of PEG and their higher fraction in the 
NGs corona at higher PEG MWs 139.  
It has been shown by us and others that the degradation kinetic of PEG-LG based 
micelles depends on the proximity of water molecules to L and G ester groups 127, 142, 
which is dependent on PEG MW and hydrophobicity of the degradable units 143, 144. 
Consequently, PEG MW had the greatest effect on NGs degradation followed by the 
fraction of less hydrophobic G in LG segments (Figure 4.3 d-f). Release kinetic of BSA 
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grafted to the NGs followed the degradation of NGs (Figure 4.3 g-i). P4-III, P8-III, and 
P12-III NGs (50% G) with PEG MW of 4, 8, and 12 kDa lost 52, 61, and 94% mass after 
12 days, respectively; those NGs released 67, 78, and 95% of the grafted BSA after 12 
days. P8-I, P8-II, and P8-III NGs ( (PEG MW 8kDa) with 25, 40, and 50% G in LG 
segments lost 30, 41, and 61% mass after 12 days incubation, respectively, those NGs 
released 58%, 62%, and 78% of the grafted BSA after 12 days. 
5. Conclusion 
Fabrication and characterization of resorbable NGs based on self-assembly of PEG 
macromers chain-extended with short L and G segments were investigated. It was shown 
that the NGs properties can be controlled by changing the molecular weight of PEG and 
ratio of L to G. For example, it was observed that degradation rate and protein release of 
the NGs increased with decreasing L to G ratio for the same PEG molecular weight. 
Therefore, these NGs can be potentially used as a carrier for temporal controlled release 
of different types of growth factors for different purposes.  
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CHAPTER 5: EVALUATING THE EXTENT OF VASCULOGENESIS AND 
OSTEOGENESIS STEM CELLS ENCAPSULATED IN A PATTERNED 
HYDROGEL WITH SPATIOTEMPORAL RELEASE OF BMP2 AND VEGF.  
1. Introduction 
The reconstruction of large bone defects with implanted scaffolds due to resection of 
tumors, skeletal trauma, or infection remains a significant clinical problem 145. The high 
clinical failure rates with allografts and implanted scaffolds are attributed to insufficient 
vascularization and slow bone regeneration 146. Engineered matrices that can guide 
concerted differentiation of multiple cell types to both vasculogenic and osteogenic 
lineages are promising for the treatment of large bone defects. In that regard, natural and 
synthetic matrices loaded with bone morphogenetic proteins (BMPs), with or without 
mesenchymal stem cells (MSCs), have been used extensively as a graft to accelerate bone 
repair and healing 147. Among BMPs, recombinant human BMP-2 (hereafter referred to 
as BMP2) is used as a potent osteogenic factor in certain clinical applications including 
spine fusion and alveolar ridge augmentation 148. Similarly, the widely used vascular 
endothelial growth factor (VEGF) is not only involved in angiogenesis, but also 
implicated in maturation of osteoblasts, ossification, and bone turnover 115, 149. As the 
bioactivity of BMP2 and VEGF is concentration and time-dependent 135-137, their 
sustained delivery from biodegradable particulate systems has been investigated 118, 120 .
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 Osteogenesis and vascularization during bone development and growth are coupled 
processes 149, 153. VEGF plays a key role in blood vessel invasion into hypertrophic 
cartilage as the endothelial cells in the invading vessels secrete growth factors that 
stimulate osteogenesis 149, 154. There is a close correlation between vascularization and 
bone formation in endochondral ossification as maximum extent of bone formation 
follows maximum levels of VEGF expression 155. In the bone marrow, endothelial 
progenitor cells form an osteoblast-vascular niche by close proximity to osteoprogenitor 
cells in the endosteum 156. Hence, several studies have investigated the combined effect 
of BMP2 and VEGF on osteogenic and vasculogenic differentiation of MSCs and 
endothelial progenitor cells (EPCs).  
 
Figure 5.1. Vasculogenesis and osteogenesis are tightly coupled processes during bone 
formation 
 
In one study 157, the extent of osteogenic differentiation of rat MSCs co-expressing 
BMP2 and VEGF in 2D culture was lower than MSCs expressing only BMP2. In another 
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study 158, in which MSCs in combination with EPCs were seeded in a calcium 
sulfate/alginate scaffold, the extent of osteogenic and vasculogenic differentiation of 
MSC+EPC group in vitro and in vivo (bone formation and blood vessel density) was 
significantly higher than the groups with only MSCs or EPCs. Furthermore in that study, 
the MSC+EPC group had higher extent of mineralization and vascularization than the 
group with BMP2-expressing MSCs. These previous studies indicate that EPCs not only 
take part in vascularization but they also enhance osteogenesis in combination with 
MSCs 159.  
There is conflicting reports on the effect of VEGF and its combination with BMP2 
on the extent of bone formation in vivo 160-162. In an in vivo study 161, BMP2-expressing 
MSCs in combination with VEGF-expressing EPCs encapsulated in an alginate gel 
showed higher extent of bone formation after intramuscular implantation compared to the 
alginate gel with MSCs and VEGF-expressing EPCs. Further, VEGF-expressing EPCs 
hindered terminal differentiation of MSCs in co-cultures of EPCs+MSCs 161. In an in vivo 
study in rat cranium 162, dual delivery of BMP2 and VEGF from gelatin nanoparticles 
embedded in a porous scaffold increased bone formation after 4 weeks implantation, but 
not after 12 weeks, compared to the delivery of BMP2 only. In addition, in an in vivo 
study in canine ulna 160, the extent of bone formation in a calcium phosphate scaffold, 
embedded with BMP2 and VEGF in poly(lactide-co-glycolide) (PLGA) nanoparticles, 
was independent of VEGF. Also, in an in vivo study in rat, dual delivery of VEGF from a 
gelatin hydrogel surrounding a solid matrix embedded with BMP2-encapsulated PLGA 
microspheres had no effect on bone formation in an orthotopic site compared to BMP2 
alone 163. However, dual and sustained delivery of BMP2 and VEGF enhanced bone 
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formation in an ectopic site 163 where MSCs and EPCs can potentially migrate from the 
surrounding tissue to the site of regeneration.  
The previous studies suggest that dual BMP2 and VEGF delivery is effective in the 
presence of both MSCs and EPCs. Further, the addition of VEGF seems to retard 
maturation of MSCs to osteoblasts. This suggests that osteogenesis and vascularization 
may be coupled by spatiotemporal regulation of paracrine signaling in which the invading 
vascular endothelial cells secrete osteogenic morphogens to stimulate MSC 
differentiation and bone formation 164.  
 
Figure 5.2. Dual delivery of BMP2 and VEGF in 21 and 10 days, respectively. 
 
We hypothesized that osteogenesis and vascularization are coupled by the spatial and 
temporal expression of morphogens secreted by the differentiating MSCs and invading 
vascular endothelial cells. In this work, we test the hypothesis in vitro with human MSCs 
(hMSCs) and human colony-forming endothelial cells (ECFCs) encapsulated in a 
patterned hydrogel with spatiotemporal release of BMP2 and VEGF. Microchannels were 
generated in lactide-chain-extended star polyethylene glycol (SPELA) hydrogel. hMSCs 
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and BMP2-grafted NGs (BMP2-NGs) were encapsulated in the SPELA hydrogel. The 
microchannels were injected with a suspension of ECFCs+hMSCs and VEGF-grafted 
NGs (VEGF-NGs) in gelatin methacryloyl (GelMA) and crosslinked. The hydrogel 
constructs were cultured in vasculogenic/osteogenic medium (without VEGF or BMP2) 
and characterized with respect to the extent of osteogenic/vasculogenic differentiation of 
hMSCs and ECFCs.  
 
 
Figure 5.3. (a) Schematic diagram for NG assembly and protein grafting. The diagram is for 
illustration of protein grafting to NGS and is not intended to show the actual nanostructure of the 
NGs. (b) Schematic diagram of vasculogenic GelMA microchannels in osteogenic SPELA gel for 
patterned constructs. The SPELA precursor solution loaded with hMSCs and NG-BMP2 was 
injected inside a Teflon cylinder (5 mm diameter and 3 mm height) fitted with 12 needles spaced 
500 µm apart. After gelation, the needles were removed and the GelMA precursor solution loaded 
with ECFCs+hMSCs and NG-VEGF was injected in the microchannels and UV crosslinked. 
After gelation, the cell-encapsulated construct was incubated in vasculogenic medium (without 
VEGF) for the first week, 50:50 mixture of vasculogenic and osteogenic medium (without VEGF, 
BMP2, and DEX) for three days (days 8-10), and finally in osteogenic medium (without DEX 
and BMP2, days 11-21).  
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2. Experimental  
2.1. Encapsulation and differentiation of hMSCs and ECFCs in the un-patterned 
constructs 
For the un-pattarned osteogenic constructs, hMSCs and BMP2-NGs were 
encapsulated in SPELA hydrogel and cultured in osteogenic medium without DEX and 
BMP2 (basal medium plus 50 µg/mL AA and 10 mM βGP). Osteogenic constructs 
included hMSCs in SPELA gel without BMP2, with dissolved BMP2, and BMP2-NGs. 
Briefly, 20 mg of BMP2-NGs (1.2 µg BMP2) were suspended in 1 mL of SPELA gel 
precursor solution [200 mg SEPLA macromer, 4 mg Ac-GRGD (2 wt% of macromer) for 
cell adhesion, and 7.5 mg (0.75 wt%) photo-initiator (Irgacure-2959, CIBA)] and the 
suspension was sterilized by filtration. Next, hMSCs at a density of 2x106 cells/mL were 
suspended in the sterile SPELA precursor solution, injected between two sterile glass 
slides, and crosslinked by exposure to UV irradiation as we previously described 134. For 
the un-patterned vasculogenic constructs, a 50:50 mixture of hMSCs+ECFCs 134 plus 
VEGF-NGs was encapsulated in GelMA hydrogel and cultured in EMB-2 BulletKit 
medium (Lonza) without the addition of VEGF. Vasculogenic constructs included 
hMSCs+ECFCs in GelMA hydrogel without VEGF, with dissolved VEGF, and VEGF-
NGs. Briefly, 2 mg VEGF-NGs (120 ng VEGF) was suspended in 1 mL of GelMA 
precursor solution (50 mg GelMA and 7.5 mg photo-initiator) and sterilized. Next, 50:50 
mixture of hMSCs+ECFCs at a total density of 2x106 cells/mL was suspended in the 
sterile GelMA precursor solution, injected between glass slides, and crosslinked by UV 
irradiation as described 134. After gelation, disk-shape gels (7 mm diameter and 0.5 mm 
thickness) were cut and incubated in PBS for 1 h with two PBS changes. Next, the media 
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was replaced with osteogenic (without DEX and BMP2) or vasculogenic (without VEGF) 
medium and incubated for 21 and 10 days, respectively.  
2.2. Encapsulation and differentiation of hMSCs and ECFCs in the patterned 
constructs 
Patterned hydrogels with GelMA micro-channels in a SPELA matrix were generated 
for osteogenic-vasculogenic co-culture experiments. Twelve 900-µm diameter needles 
(G-20) were inserted through the end-caps of a Teflon cylinder with diameter and height 
of 5 and 3 mm, respectively. The distance between the needles was 500 µm. Next, the 
sterile SPELA precursor solution (200 mg SPELA macromer, 4 mg Ac-GRGD, 7.5 mg 
photo-initiator, 20 mg BMP2-NGs, and 2x106 hMSCs in 1 mL PBS) was injected 
between the needles and crosslinked with UV as described (Figure 5.3 b) 134. Then, the 
needles were removed and the GelMA precursor solution (50 mg GelMA, 7.5 mg photo-
initiator, 2 mg VEGF-NGs, and 2x106 hMSCs/ECFCs in 1 mL PBS) were injected in the 
channels and crosslinked with UV as described (Figure 5.3 b) 134. After gelation, the 
patterned constructs were washed with PBS and incubated in vasculogenic medium 
(without VEGF) for the first week, 50:50 mixture of vasculogenic and osteogenic 
medium (without VEGF, BMP2, and DEX) for the next three days (days 8 -10), and 
finally in osteogenic medium (without DEX and BMP2) for 11 days (days 11-21). 
Experimental groups included patterned constructs without BMP2/VEGF, BMP2 
dissolved in SPELA gel plus VEGF in GelMA, and BMP2-NGs in SPELA gel plus 
VEGF-NGs in GelMA.  
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2.3. Characterization of cells behavior encapsulated in patterned and un-patterned 
hydrogels  
Biochemical, mRNA, and protein analysis, alizarin red and Immunofluorescent 
staining techniques were used to characterized the extent of osteogenesis and 
vasculogenesis of cells in hydrogels.  
3. Results 
3.1. Osteogenic differentiation of hMSCs and ECFCs encapsulated in patterned 
hydrogels with BMP2 and VEGF NGs  
DNA content, ALP activity, calcium content, and mRNA expression of osteogenic 
markers for ECFCs+hMSCs/NG-VEGF encapsulated in GelMA channels and 
hMSCs/NG-BMP2 encapsulated in SPELA matrix in the patterned constructs are shown 
in Figure 5.4 (blue curve). Controls included ECFCs+hMSCs in the channels and hMSCs 
in the matrix with (red curve, without NG grafting) and without (green curve) VEGF and 
BMP2 in the channels and matrix, respectively. Other controls included hMSCs/BMP2 
(dashed pink) and hMSCs/NG-BMP2 (dashed light blue) in SPELA gel (no GelMA 
channels) and cultured in osteogenic medium (without DEX and BMP2) for 21 days. 
DNA content of the groups with BMP2/VEGF (with or without  NG grafting) decreased 
significantly with time which was related to the differentiation of encapsulated cells, as 
we previously described 165 (Figure 5.4 a). ALP activity of hMSCs in un-patterned 
osteogenic constructs with BMP2 or BMP2-NGs (dashed curves) increased significantly 
from day 7 to 14, reached a maximum after 14 days and decreased from day 14 to 21 
(Figure 5.4 b). The peak ALP activity of hMSCs in the patterned constructs with 
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BMP2/VEGF (with or without grafting) was delayed to day 18 because the constructs 
were cultured in vasculogenic medium in the first 7 days (Figure 5.4 b). The patterned 
constructs (solid lines) had higher ALP activity than their corresponding un-patterned 
osteogenic constructs (dashed lines). The patterned constructs with NG-BMP2/NG-
VEGF (blue curve) and without BMP2/VEGF (green curve) had the highest and lowest 
ALP activity with 6100±500 and 2000±300 IU/mg DNA, respectively. Calcium content 
as a measure of the extent of mineralization for all groups steadily increased with 
incubation time (Figure 5.4 c). After 21 days incubation, the patterned constructs (solid 
lines) had higher calcium content than their corresponding un-patterned osteogenic 
constructs (dashed lines). The patterned constructs with NG-BMP2/NG-VEGF (blue 
curve) and without BMP2/VEGF (green curve) had the highest and lowest calcium 
content after 21 days with 710±50 and 220±30 mg/mg DNA, respectively (Figure 5.4 c). 
mRNA expression of RUNX2 transcription factor initially increased with incubation 
time for all groups, peaked at day 14, and then decreased. The un-patterned osteogenic 
construct with NG-BMP2 and the patterned construct with NG-BMP2/NG-VEGF had the 
highest RUNX2 expression while the patterned construct without BMP2/VEGF had the 
lowest RUNX2 expression (Figure 5.4 d). Interestingly, RUNX2 expression of the 
patterned construct with NG-BMP2/NG-VEGF decreased slightly with incubation after 
day 14 (Figure 5.4 d). mRNA expression  of ALP (Figure 5.4 e) followed a trend similar 
to that of ALP activity shown in Figure 5.4 b. 
 The patterned construct with NG-BMP2/NG-VEGF (blue curve) had highest ALP 
expression at day 14. mRNA expression for Col I for all groups increased steadily with 
incubation time (Figure 5.4 f). The un-patterned osteogenic construct with NG-BMP2 
74 
 
and the patterned construct with NG-BMP2/NG-VEGF had the highest Col I expression 
after 21 days incubation. 
 
 
Figure 5.4. DNA content (a), ALP activity (b), calcium content (c), and mRNA expression of 
osteogenic markers Runx2 (d), ALP (e), and Col I (f) for hMSCs and ECFCs in the patterned 
constructs. Groups included patterned constructs without VEGF/BMP2 (green), with 
VEGF/BMP2 (red), and with NG-VEGF/NG-BMP2 (blue); un-patterned constructs with NG-
BMP2 (dashed light blue) and with BMP2 (dashed pink). Patterned constructs were incubated in 
vasculogenic medium for 7 days, vasculogenic/osteogenic medium for 3 days, and osteogenic 
medium for 11 days (without VEGF, BMP2, and DEX). Un-patterned constructs were incubated 
in osteogenic medium without DEX and BMP2 for 21 days. (e) Alizarin red stained (dark red) 
images of the patterned constructs along the length of a microchannel with none, dissolved, and 
NG-grafted BMP2/VEGF after 4 and 21 days of incubation. BMP2 and VEGF in NG-VEGF/NG-
BMP2 group have 21 days and 10 days release, respectively.One star indicates statistically 
significant difference (s.d.; p<0.05) between the test group and None (green); two stars between 
the test group and BMP2/VEGF (red). Error bars correspond to means ± 1 SD for n=3. 
 
The images in Figure 5.4g show Alizarin red staining along the length of a 
microchannel for the patterned constructs with none, dissolved, and NG-grafted 
BMP2/VEGF after 4 and 21 days of incubation. The image for patterned construct with 
NG-grafted BMP2/VEGF after 21 days (bottom right image) showed significantly higher 
staining in the matrix (dark red) and lower staining in the channels compared to the other 
groups.  
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3.2. Vasculogenic differentiation of hMSCs and ECFCs encapsulated in patterned 
hydrogels with BMP2 and VEGF NGs 
DNA content, CD31 protein, and mRNA expression of vasculogenic markers for 
ECFCs+hMSCs/NG‐VEGF encapsulated in GelMA channels and hMSCs/NG‐BMP2 
encapsulated in SPELA matrix in the patterned constructs are shown in Figure 5.5 (blue 
curve). Controls included ECFCs+hMSCs in the channels and hMSCs in the matrix with 
(red curve, without NG grafting) and without (green curve) VEGF and BMP2 in the 
channels and matrix, respectively. Other controls included ECFCs+hMSCs/VEGF 
(dashed pink) and ECFCs+hMSCs/NG‐VEGF (dashed light blue) in GelMA (no SPELA) 
and cultured in vasculogenic medium (without VEGF) for 21 days. DNA content of the 
groups with BMP2/VEGF (with or without NG grafting) decreased with time with 
differentiation of the encapsulated cells 134 (Figure 5.5 a). CD31 protein expression for 
the patterned construct without BMP2/VEGF (green curve) did not increase significantly 
with time (Figure 5.5 b,c). CD31 expression of the un-patterned vasculogenic constructs 
with VEGF (dashed pink) or NG-VEGF (dashed light blue) increased with time but the 
CD31 expression for the NG-VEGF construct was significantly higher than that of VEGF 
(Figure 5.5 b,c). The patterned constructs (solid lines) had higher CD31 expression than 
the un-patterned vasculogenic constructs (dashed lines) for all incubation times. For 
example after 10 days of incubation, CD31 expressions for patterned constructs with NG-
BMP2/NG-VEGF and BMP2/VEGF were 0.91±0.08 and 0.75±0.12, respectively; the 
expressions for the un-patterned vasculogenic constructs were 0.78±0.12 and 0.52±0.07. 
For all time points, CD31 expression of patterned construct with NG-BMP2/NG-VEGF 
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was higher than the other groups. mRNA expressions of vWF, CD31, and VE-cadherin 
(Figure 5.5 d-f) with incubation time were consistent with the CD31 protein expression in 
Figure 5.5 b. The patterned construct with NG-BMP2/NG-VEGF (blue curve) had higher 
expression of vWF, CD31, and VE-cadherin than the other groups for all time points.  
 
Figure 5.5. DNA content (a), CD31protein expression (b), representative western blot bands 
(c), and mRNA expression of vasculogenic markers vWF (d), CD31 (e), and VE-cadherin (f) for 
hMSCs and ECFCs in the patterned constructs (see Figure 5.4 for the groups). (e) CD31 stained 
(green) images of the patterned constructs along the length of a microchannel with none, 
dissolved, and NG-grafted BMP2/VEGF after 4 and 10 days of incubation. BMP2 and VEGF in 
NG-VEGF/NG-BMP2 group have 21 days and 10 days release, respectively. One star indicates 
statistically significant difference (s.d.; p<0.05) between the test group and None (green); two 
stars between the test group and BMP2/VEGF (red). Error bars correspond to means ± 1 SD for 
n=3. 
The images in Figure 5.5 g show CD31 staining (green) along the length of a 
microchannel for the patterned constructs with none, dissolved, and NG-grafted 
BMP2/VEGF after 4 and 10 days of incubation. The image for patterned construct with 
NG-grafted BMP2/VEGF after 10 days (bottom right image) showed significantly higher 
CD31 expression in the channel compared to the other groups. 
bFGF protein expression of the un-patterned osteogenic, patterned, and un-patterned 
vasculogenic constructs are shown in Figures 5.6 a-c, respectively. For a given time 
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point, patterned constructs and the un-patterned osteogenic constructs had highest and 
lowest expression of bFGF, respectively, with or without protein grafting. For a given 
culture system, the groups with grafted proteins had the highest expression of bFGF after 
14 and 21 days of incubation. Overall, the patterned construct with NG-BMP2/NG-
VEGF had highest expression of bFGF after 14 and 21 days among all groups (Figure 5.6 
b). For example, bFGF expression of the patterned construct with none, dissolved, and 
NG-grafted BMP2/VEGF after 21 days incubation was 160±7, 54±4, and 23±1 ng/mL, 
respectively (Figure 5.6 b); those of the un-patterned vasculogenic constructs was 
110±12, 48±4, and 19±5 ng/mL (Figure 5.6 c); and those of the un-patterned osteogenic 
constructs was 49±7, 14±4, and zero ng/mL (Figure 5.6 a). In addition, the effect BMP2 
and VEGF release rate in patterned constructs on bFGF protein expression has been 
shown in figure 5.6.  
The groups with 21 days release of BMP2 and 10 days release of VEGF (dashed blue 
curve) had the highest bFGF expression compared to the other two groups with 10 days 
or 21 days release for both BMP2 and VEGF (dashed green and red curves) with 149±9 
and 120±6 ng/ml bFGF expression, respectively, after 21 days.It should be mentioned 
that there was no significant difference between the bFGF expression of NG(21)-
BMP2/NG(10)-VEGF and NG(10)-BMP2/NG(10)-VEGF groups.  
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Figure 5.6. bFGF protein expression of the un-patterned osteogenic (a), patterned (b), and 
un-patterned vasculogenic (c) constructs with incubation time for the groups with none, 
VEGF/BMP2, and NG(21)-BMP2/NG(10)-VEGF. (d) Effect of BMP2 and VEGF release rate on 
bFGF protein expression of patterned construct.  Groups included patterned constructs without 
VEGF/BMP2 (green, c), with VEGF/BMP2 (red, c), and with NG(21)-BMP2/NG(10)-VEGF 
(blue, b); un-patterned osteogenic constructs with NG(21)-BMP2 (light blue, a) and with BMP2 
(pink, a); and un-patterned vasculogenic constructs with NG(10)-VEGF (dashed light blue in b) 
and with VEGF (dashed pink in b). Groups with NG(21)-BMP2/NG(10)-VEGF (dashed blue in 
d), NG(21)-BMP2/NG(21)-VEGF (dashed red in d) and NG(10)-BMP2/NG(10)-VEGF (dashed 
green in d) shows patterned construct with different protein release rate. The numbers in 
abbreviations NG(21) and NG(10) represent the release time of grafted proteins on each type of 
NG. One star indicates statistically significant difference (s.d.; p<0.05) between the test group 
and None (green); two stars between the test group and BMP2 (pink in a) or VEGF (dashed pink 
in b) or BMP2/VEGF (red in c) or NG(21)-BMP2/NG(21)-VEGF (dashed red in d). Error bars 
correspond to means ± 1 SD for n=3. 
  
4. Discussion  
It has been reported that the extent of bone formation in vivo depends on the duration 
of BMP2 exposure to MSCs in the first four weeks 135, 136 whereas vascularization 
depends on VEGF exposure to endothelial progenitor cells within the first week 137. 
Therefore, P8-I NGs with 90% BSA release in 24 days and P12-II NGs with 70% BSA 
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release in 7 days were used for timed release of BMP2 and VEGF in the osteogenic 
SPELA matrix and vasculogenic GelMA channels, respectively. 78% and 71% of the 
grafted VEGF and BMP2 proteins, respectively, were released at a constant rate for 7 and 
21 days, without an initial burst release 150, in the enzymatically-active conformation. 
Comparison of BSA (70 kDa) release curves with those of VEGF (40 kDa) and BMP2 
(26 kDa) indicated that the protein release was dominated by the NGs degradation. PLGA 
and heparin-functionalized PLGA nanoparticles have previously been used for BMP2 
delivery and gelatin microparticles have been used for VEGF. Attachment of BMP2 to 
heparin-functionalized PLGA (90 kDa) nanoparticles and their encapsulation in a fibrin 
gel prolonged the release to 2 weeks, but the fraction of bioactive BMP2 released was 
23% compared to 57% for untreated PLGA nanoparticles 121. Encapsulation in gelatin 
microspheres prolonged VEGF release to 2 weeks but <45% of the protein was released 
from the microparticles 150. In another study, the fraction of bioactive BSA released from 
PLGA (45 kDa) nanoparticles increased from 50% to 70% after 1 week incubation by 
copolymerization of PLGA with PEG (5 kDa) 120. We previously reported that the release 
of BMP2 can be extended to 4 weeks by grafting to succinimide-functionalized blend of 
ULMW-PLA/PLEOF nanoparticles but <50% of the released protein was enzymatically 
active 118. Release kinetic of VEGF and BMP2 from PaLGb-Lc NGs (Figure 4.3 g) 
suggests that hydrophilic NGs are a more efficient platform for grafting and timed-release 
of proteins than hydrophobic PLGA nanoparticles. The lower bioactivity of BMP2 
released from PLGA nanoparticles could be attributed to protein denaturation by acidic 
degradation products of PLGA and protein adsorption/unfolding 122. 
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Several recent studies have investigated the combined effect of VEGF and BMP2 on 
osteogenesis and vascularization 157, 158, 160-162. Based on previous experimental results, 
co-expression of BMP2 and VEGF in MSC cultures had no effect on the extent of 
mineralization in vitro. On the other hand, combination of MSCs and EPCs in a calcium 
sulfate scaffold without over-expression of BMP2 showed higher mineralization in vitro 
compared to BMP2-expressing MSC only group 158. Dual delivery of VEGF and BMP2 
in vivo increased bone formation only at early time points but it was relatively 
independent of VEGF at late time points 160, 162, 163. In another study, combination of 
BMP2-expressing MSCs and VEGF-expressing EPCs in a scaffold significantly 
increased bone formation after intramuscular implantion in rat 161. The previous results 
indicate that dual delivery of BMP2 and VEGF increases osteogenesis only in MSC and 
EPC co-cultures. Our results in Figures 5.4 and 5.5 demonstrate that localized, dual 
delivery of VEGF to ECFCs+hMSCs in the channels and BMP2 to hMSCs in the matrix 
significantly increased the extent of mineralization and vascularization. Further, localized 
timed-release of VEGF in the channels and BMP2 in the matrix by grafting to NGs 
significantly improved mineralization and vascularization (blue curves in Figures 5.4-5.5) 
compared to direct addition of growth factors (red curves in Figures 5.4-5.5). 
These results suggest that differentiation and maturation of MSCs and ECFCs to 
osteoblasts and endothelial cells induced by BMP2 and VEGF, respectively, may be 
indirectly coupled; that is differentiation of ECFCs+hMSCs in the channels by VEGF 
leads to the release of osteogenic factors that diffuse to the matrix to stimulate 
osteogenesis. bFGF is shown to mediate vascularization and bone formation in MSC 
seeded scaffolds 166, 167. Therefore, we measured the expression of bFGF at the protein 
81 
 
level for the un-patterned and patterned constructs (Figure 5.6). The un-patterned 
vasculogenic construct without VEGF expressed low levels of bFGF after 7 and 10 days 
incubation (green in c) whereas the un-patterned osteogenic construct without BMP2 did 
not express bFGF in 21 days (green in a). The un-patterned vasculogenic construct with 
VEGF (dashed pink and blue in c) had higher expression of bFGF than the un-patterned 
osteogenic construct with BMP2 (dashed pink and blue in a). bFGF expression of the 
patterned construct with direct addition of BMP2/VEGF (red in b) was comparable to 
those of un-patterned vasculogenic construct with VEGF (dashed pink in c). Overall, 
timed-release of NG grafted BMP2/VEGF significantly enhanced bFGF expression level 
in un-patterned (dashed pink in a,c) and patterned (blue in b) constructs. However, timed-
release of BMP2/VEGF in the patterned construct sharply increased bFGF expression 
level after 14 and 21 days (blue in b) compared to direct addition of the growth factors 
(red in b). The results with NG-BMP2/NG-VEGF support previous reports on the effect 
of timed-release of VEGF and BMP2 on vascularization and osteogenesis, respectively 
168-170
.  
During endochondral ossification, maximum levels of VEGF precede maximum 
levels of new bone formation 155. In the mineralization front, differentiated vascular 
endothelial cells in the invading vessels secrete growth factors that stimulate 
differentiation of MSCs to the osteogenic lineage 149. Consistent with the process of bone 
development in vivo, bFGF expression levels in Figure 5.6 suggests that the differentiated 
ECFCs+hMSCs in the channels secret bFGF, and possibly other growth factors, that 
synergistically enhance osteogenic differentiation of hMSCs and mineralization. The data 
in Figure 5.6 also indicates that timed-release of NG-grafted VEGF in the channels leads 
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to sustained production of bFGF in the first week of co-culture to stimulate maturation of 
the differentiated cells to osteoblasts and endothelial cells. 
5. Conclusion 
We investigated the effect of spatial and temporal release of BMP2 and VEGF on the 
extent of osteogenic and vasculogenic differentiation of hMSCs and ECFCs encapsulated 
in a patterned hydrogel. For timed-release, BMP2 and VEGF were grafted to resorbable 
NGs based on self-assembly of PEG macromers chain-extended with short L and G 
segments. Degradation rate and protein release of the NGs increased with decreasing L to 
G ratio. Based on NGs release profile, P12-II NGs with 12 kDa PEG MW, 12 LG 
segment length, and 60/40 L/G ratio was selected for VEGF grafting and release in 7 
days. P8-I NGs with 8 kDa PEG MW, 13 LG segment length, and 60/40 L/G ratio was 
selected for BMP2 grafting and release in 21 days. Enzymatic activity of the released 
VEGF and BMP2 after 7 and 21 days was 80% and 71%, respectively. hMSCs and 
ECFCs were encapsulated in patterned hydrogels with NG-grafted proteins; that is, 
hMSCs and BMP2-NGs encapsulated in SPELA matrix and hMSCs+ECFCs and VEGF-
NGs in GelMA microchannels. Control groups were hMSCs in the un-patterned SPELA 
and hMSCs/ECFCs in the un-patterned GelMA. Based on the results, the extent of 
osteogenic and vasculogenic differentiation of hMSCs and ECFCs was higher in 
patterned constructs compared to un-patterned constructs. The addition of VEGF-NGs in 
the channels and BMP2-NGs to the matrix significantly increased osteogenic and 
vasculogenic differentiation of hMSCs and ECFCs compared to the addition of VEGF 
and BMP2. The patterned constructs with timed-release of NG-grafted VEGF and BMP2 
had highest extent of osteogenic and vasculogenic differentiation. Further, timed-release 
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of NG-grafted VEGF in hMSC+ECFC seeded channels and NG-grafted BMP2 in hMSC-
seeded matrix sharply increased bFGF expression after 21 days in the co-cultured 
constructs. The results suggest that mineralization and vascularization may be coupled by 
localized secretion of paracrine signaling factors like bFGF by differentiating hMSCs and 
ECFCs.  
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CHAPTER 6: FUTURE WORK 
Traditional attempts to grow bone grafts in the laboratory were based on culturing 
cell/scaffold constructs under static conditions in the presence of osteogenesis-inducing 
factors. However, static cultures are not optimal to grow centimeter-sized bone grafts for 
clinical translation due to poor nutrient supply and removal of metabolic waste. Under 
these conditions, in fact, mass transport occurs only via diffusion, which is not sufficient 
to support cell survival and proliferation inside the core of large cell/scaffold constructs, 
resulting in necrosis and poor tissue formation. In addition, cell proliferation and matrix 
synthesis at the construct periphery over the culture period further impede medium 
diffusion and contribute to the formation of a nutrient gradient that drive cell migration 
towards the substitute borders 171. On top of this, culture in static conditions does not 
allow provision of those biophysical stimuli that are critical for functional regeneration 
172, 173
. In fact, bone cells are sensitive to mechanical stimuli, whose integration and 
conversion into intracellular signals play an important role in driving bone remodeling 
throughout lifetime and regeneration during fracture healing 174, 175. Human bone is 
principally subjected to two types of mechanical stimuli, i.e., strain caused by 
deformation (bending and compression) resulting from physical activity (estimated 
values <2000 µε), and fluid shear stress resulting from interstitial fluid movement 
through the lacunae as a consequence of loading (estimated values 0.8–3 Pa) 176. 
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Conversion of physical stimuli into molecular signals and biological responses is 
termed mechanotransduction, which principally relies on the regulation of stretch-
activated ion channels and integrin-initiated cytoskeleton deformations and organelle 
displacement 177  that ultimately triggers the initiation of a cascade of events culminating 
in the activation of genes involved in osteogenic pathways 176. Based on this knowledge, 
it is clear that the recapitulation of these mechanisms in vitro is essential for fostering the 
regenerative properties of human osteocompetent cells seeded onto biomaterial scaffolds, 
thus enabling the formation of mature tissue substitutes for enhanced skeletal 
reconstructions. Advances in bioreactor systems over the last two decades have opened 
new possibilities in the field of bone engineering as they allow to nurture the 
development of bone tissue by providing an appropriate physiological environment with 
stimulatory biochemical and biophysical signals 178. The combination of stem cells, 
biomaterials, osteogenesis-inducing factors and bioreactor systems has recently been 
defined as the “Tissue Engineering Quadriad” 179, with the culture under dynamic 
conditions representing a paradigm shift for the ex vivo construction of viable tissue 
substitutes for replacement and reconstructive therapies. Not least, the construction of 
viable bone substitutes using bioreactor systems opens new opportunities for the 
generation of valid experimental models to study bone development and pathologies, 
screen new drugs and test biomaterials within a context that better reflects the native 
tissue environment. Therefore, the first step in the future would be evaluating the extent 
of osteogenesis and vasculogenesis of stem cells in the engineered shell-core composite 
with timed and localized delivery of BMP2 and VEGF with respect to mineralization and 
vascularization in vitro in a dynamic direct perfusion bioreactor.  
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Figure 6.1. Schematic representation of direct perfusion bioreactor. In direct perfusion 
bioreactors the cell/scaffold constructs are placed in a press-fitted fashion in the culture chamber 
and the medium is perfused throughout the constructs. 
 
To design the bioreactor system, microtubular shells with 8 mm outer diameter and 3 
mm wall thickness will be used to direct the flow of osteogenic medium in the hioreactor 
of a perfusion cell culture. The interconnected microcanals of the shell will be injected 
with a mixture of BMP2  (200 ng/mL) and 5xlob hMSCs in collagen type I. The scaffolds 
will be press-fitted into a silicone tube to yield the bioreactor section of the perfusion 
system (Figure 6.2 b). The medium will be oxygenated in the reservoir which has one 
inlet and 16 outlets to allow simultaneous perfusion of 16 shells (Figure 6.2 a).   
Factors that affect the transport of nutrients and oxygen in the central part of the 
engineered shell-core graft are the spacing between the Volkmann canals in the rigid 
shell and the spacing between the microchannels in the soft core (Figure 1.2).  
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Figure 6.2. 16 perfusion bioreactors in parallel (arrow shows one of the reactors). (b) The 
perfusion cell culture system. 
 
The average wall thickness of osteons in the native compact bone is 150 µm 180. 
Therefore for 5-µm microsheet thickness, microtubes will consist of 30 lamellar layers. 
The spacing between the Volkmann canals in the natural bone varies between 500-1000 
µm 181.  Therefore, microdrilling will be used to vary the spacing between the Volkmann-
like canals in the engineered graft from 500 to 750 and 1000 µm. The spacing between 
the needles in the soft GeIMA gel will also be varied from 500 to 750 and 1000 µm. The 
rigid shell will be synthesized as described before 181. An array of circular microholes 
with intervals of 500, 750, or 1000 µm will be drilled by laser microdrilling on the 
outside surface of the shell traversing the shell thickness. Next, the shell will be sterilized 
and all subsequent steps will be done under sterile condition. Then, needles with 
separation distance of 500-1000 µm will be placed inside the shell through an end-cap. 
The sterile GeIMA precursor solution, NG-VEGF, and human MSCs+EPCs (50:50, 2xl06 
cells/ml of GeLMA) will be injected between the needles and cross-linked with UV as we 
described previously 182 and needles are removed. Finally, the interconnected microcanals 
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of the shell wall will be filled with NG-BMP2 and human MSCs (2x106 cells/ml 
collagen) in collagen type I solution. The cellular constructs with timed-release of growth 
factors will be press-fitted into a silicone tube as the bioreactor section of the perfusion 
system (Figure 6.2 b) and culture medium will pumped through the bioreactors at the rate 
of 0.5 mL/min for 21 days as described. At each time point (1, 3,7. 10, 14. 21), the 
middle section of the graft will he characterized with respect to cellularity, extent of 
mineralization, and extent of vascularization as we previously described 134, 182, 183. 
Microvessels will be visualized with Image ProPlus software to determine uniformity and 
total capillary density as described 35. 
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